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 Abstract 
 
Skin cancer is one of the most common forms of adult solid tumour. The incidence is 
increasing rapidly making skin cancer a major health problem in several countries.   
Cutaneous Malignant Melanoma (CMM) is the least common but the most life 
threatening type of skin cancers and is responsible for 90% of all skin malignancy 
associated deaths.  
The precise cellular and molecular etiology of malignant melanoma is quite complex 
and the molecular events directly related to melanoma progression are yet to be 
elucidated. However, recent advances in molecular biology have resulted in a clearer 
understanding of the cellular and molecular events of skin cancer development. The 
best-characterized locus associated with CMM development is the CDKN2A that maps 
to chromosome 9p21 and encodes for the cell cycle regulator p16 tumour suppressor 
gene (TSG), and is frequently inactivated in melanoma tumours. In addition to p16, 
other loci located in 9p21 appear to be important in CMM development and functional 
evidence for the presence of TSG(s) has been provided (Parris et al., 1999). The aim of 
our study is to contribute to the understanding of CMM development by isolating and 
characterising novel TSG(s) at this location.  
 In order to pursue identifying potential TSG(s), we have developed several 
monochromosome hybrids using microcell mediated chromosome transfer, and 
evaluated the tumourigenicity of the constructed hybrids by anchorage independent 
growth in soft agar. For the molecular biology aspects, expression analysis of the genes 
in the 9p21 region was carried out by reverse transcription PCR.  Potential candidate 
tumour suppressor genes were then carefully evaluated by generating expression 
profiles via conducting real time PCR. Experimental evidence is provided which 
supports the candidacy of interferon alpha 1 (IFNA1) as a tumour suppressor gene for 
melanoma development. 
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CHAPTER 1 
 
 
INTRODUCTION 
 
 
CHAPTER 1: INTRODUCTION 
 
1.1. Skin cancer 
 
1.1.1. Incidence 
 
Skin cancer is one of the most common forms of cancer. In fact, one in three 
cancers are skin-related (WHO, 2005). The incidence is increasing rapidly making 
it a major health problem in several countries.  Official figures show that the 
occurrence of skin cancer has doubled in the past decade in the UK which makes 
it the seventh most common form of cancer. There were 70,038 cases registered in 
the UK in 2001 including 7,300 cases of melanoma (Cancer Research UK, 2005). 
The same source indicates that not only the number of skin cancer patients is 
increasing but also the mortality. In fact, in 2003, 2,280 people died from skin 
cancer of which 1,770 were attributable to malignant melanoma.  
In the United States, skin cancer accounts for about half of all cancers and affects 
approximately one million Americans every year (American Cancer Society, 
1999). Moreover, it is estimated that approximately 60,000 new cases of 
 
1 
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melanoma have been reported and 8,110 melanoma related deaths in 2007 (Jemal 
et al., 2007). However, Australia has the highest skin cancer incidence in the 
world where over 382,000 people are treated for skin cancer and over 1400 die 
each year (The Cancer Council Australia, 2006).  
 
1.1.2. Skin biology and structure 
 
The skin is the largest organ of the body. It has several roles, it is responsible for 
shielding the rest of the body from excessive light and extreme temperatures 
(Poole and Guerry, 2005), protecting the body from infection and injury. The skin 
is kept clean from excess of deleterious substances by the action of sweat glands. 
The human skin is composed of two layers: epidermis (outer layer) and dermis 
(inner layer), and below them is the subcutaneous layer also called subcutis 
(Figure 1.1).  
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Figure 1.1: A diagram showing the structure of the skin. The outer surface is the 
epidermis and the lower layer is the dermis much thicker and composed of 
connective tissue, blood vessels, nerve endings, hair follicles, sweat and oil glands. 
However, most skin cancers develop from the epidermis (image from MacNeil, 
2007). 
 
Most skin tumours arise from the epidermis which contains three different cell 
types that correspond to the 3 types of skin cancer.  In other words, the names 
Basal Cell Carcinoma, Squamous Cell Carcinoma and Cutaneous Malignant 
Melanoma originate from the types of cells that they derive from. For instance, 
melanoma is the uncontrolled growth of melanocytes located in the lower part of 
the epidermis (Figure 1.2). Melanocytes function is the synthesis of the pigment 
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called melanin that gives the skin its colour (Montagna and Prakkal, 1974; 
Slominski et al., 2001). 
 
Figure 1.2: Histology of a normal skin (left): the dermis and epidermis are clearly 
delineated with a non proliferative layer of melanocytes between them. Histology 
of melanoma skin (right): Highly proliferative melanocytes represented by dark 
staining cells (stained with hematoxylin and eosin, and viewed on a 
microscope slide, from www.Pathologypics.com) 
  
1.1.3. Types of skin cancer  
There are three common types of skin tumour: 
 
1.1.3.1. Basal Cell Carcinoma (BCC): 
 
First described in 1827, BCC is the most common malignancy, also called basal 
cell epithelioma but the term carcinoma is widely used to describe this tumour. 
This type of tumour arises from the basal cells of the epidermis and it can develop 
into a very large size lesion if neglected by the patient leading to destruction of 
Chapter 1: Introduction             
 
       Page 5
   
 
the skin or disfigurement at the site of the lesion. It usually occurs on chronic sun 
exposed sites such as face and neck. 
BCC of higher risk for metastasizing are those of long duration, larger then 2cm, 
located in the mid-face or ear region and metastatic sites have been described 
most commonly in lung, bone and lymph nodes (Ionescu et al., 2006). However, 
metastasis appears very rarely in basal cell carcinoma. 
Like most skin cancers, sun exposure plays a role in the development and 
transformation of BCC, in addition there are other risk factors such as exposure to 
arsenic, coal tar derivative and irradiation (Crowson, 2006). In white populations 
in USA, the incidence of basal cell carcinoma has increased at more than 10% a 
year (Miller et al., 1994). Also, 53,000 new cases of BCC are estimated every 
year in the UK and figures are continuing to rise on a yearly basis (Bath-Hextall et 
al., 2007).  
 
1.1.3.2. Squamous Cell Carcinoma (SCC): 
 
Squamous cell cancer is a malignant skin lesion that affects the epidermis and is 
derived from the epidermal keratinocytes. It is usually painless initially, but may 
become painful with the development of larger and invasive lesions that do not 
heal if neglected. SCC is common on white and Caucasian skin and it appears to 
be due to excessive exposure to UV light but it can also arise from industrial 
exposure such as x-ray, tar or coal (MacKie, 1996). 
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Cutaneous SCC is divided into categories of low, intermediate and high risk based 
on the malignant potential and an additional category reserved for those rare 
subtypes whose origin cannot be accurately assigned (Cassarino et al., 2006). 
Studies have revealed that in more than 90% of SCCs, as in most BCCs, 
inactivation of p53 by induced mutagenesis plays a key role in the pathogenesis of 
both non- melanoma skin cancers (Campbell et al., 1993; Brasch et al., 1997).  
In addition, SCCs tend to arise from premalignant lesions such as actinic 
keratoses (AK) also known as solar keratoses. They are extremely common skin 
neoplasm and develop as a consequence of prolonged exposure to UV radiation. 
There are strong similarities between AK and SCC both at the histological and 
molecular levels and it can sometimes be difficult to distinguish between them 
clinically (Chia et al., 2007). A proportion of 5 to 20% of AKs will progress in 10 
to 25 years to superficial squamous cell carcinoma. However, the progression 
towards SCC might be increased in immuno-compromised patients such as organ 
transplant recipients who are more likely to develop AKs (Salasche, 2000; 
Euvrard et al., 1995).          
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
1.2. Cutaneous malignant melanoma 
 
Malignant melanoma represents the fifth and sixth most common cancers in men 
and women, respectively, in the US. Also, the average lifetime risk is estimated at 
1 in 75 that shows increasing rates during the last decades (Pho et al., 2006). 
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1.2.1. History of melanoma 
 
Melanoma was referred to in ancient literature. Melanotic masses were found 
approximately 2400 years ago on the extremities of nine Colombian Inca 
mummies of Peru, also metastases were detected on their bones particularly the 
skull (Urteaga and Pack, 1966). The first description of melanoma was by 
Hippocrates in the 5
th
 century BC, who referred to it as black tumour (melas: 
black / oma: tumour) (Urteaga and Pack, 1966).   
However, the first description of melanoma as a disease was by René Laennec 
(Faculté de Médecine in Paris) in 1812 (Chin et al., 1998). Furthermore, Norris 
identified in 1820 that melanoma is a hereditary disease in the case of two family 
members having tumours originated from moles and other relatives having “many 
moles of various parts of their bodies” (Palamaras and Stavrianeas, 2004). 
 
1.2.2. Types of cutaneous malignant melanoma 
 
CMM is classified into four principal types that are distinct from each other 
regarding to etiology, biological properties and prognosis (Weyers et al., 1999). 
Pictures of the different types of melanoma are shown in Figures 1.3, 1.4, 1.5, 1.6. 
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1.2.2.1. Superficial spreading melanoma 
 
It is the most common type accounting for 65-70% of diagnosed melanomas and  
is most frequently localised in the legs for women and the trunk for men 
especially the back. The growth consists in two phases (biphasic), starting by an 
initial growth phase and followed by a vertical growth when melanocytes invade 
deeply the dermis (Figure 1.3). 
 
 
Figure 1.3: A melanoma of the superficial spreading type showing a flat lesion                     
with irregular borders. The pigmentation varies from light to dark shades (Poole 
and Guerry, 2005).  
 
1.2.2.2. Nodular melanoma 
   
It is most commonly found in middle-aged people and occurs in the back and 
chest. It accounts for 12% of all cutaneous melanomas and spreads almost 
exclusively in a vertical phase only. These nodular lesions are very aggressive and 
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develop quickly and they tend to be more common in women than men 
(Figure1.4). 
 
 
 
Figure 1.4: Nodular melanoma that has only vertical growth phase. It appears as a 
black dome that can however have a dark brown, red or blue colour (Poole and 
Guerry, 2005). 
 
1.2.2.3. Lentigo malignant melanoma 
 
It is most commonly found on the face and neck, particularly in older people. It 
grows slowly and may take several years to develop and can remain in a non-
invasive form for years but will penetrate into the deeper layers of the epidermis, 
increasing the potential of metastases (Cancerbackup 2003). It is associated with 
intense sun exposure and occurs usually in areas of the body that have been 
chronically exposed to solar radiation (Figure 1.5). 
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Figure 1.5: A lentigo malignant melanoma on the cheek of an old person showing 
a bumpy surface which is a marker of vertical growth phase and may be invasion  
(Poole and Guerry 2005). 
 
1.2.2.4. Acral lentiginous melanoma 
 
It is a form of malignant lentigo melanoma that occurs in palms, soles, and 
subungual. It is the most common melanoma in dark skinned populations and the 
least common among caucasians (Figure 1.6). 
 
 
 
     Figure 1.6: A form of acral lentiginous melanoma that grows under the foot. This     
type of melanoma does not appear to be related to UV exposure (Poole and Guerry, 
2005). 
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Apart from the skin, melanoma can occur in other locations of the body such as 
the eye called uveal melanoma which appears as a small freckle beneath the retina 
and can eventually metastasise. 
Other uncommon melanomas are amelanotic (no melanin pigment), desmoplastic 
which are often amelanotic and the head and neck are the most common location 
for occurrence (reviewed in Foote et al., 2008). Desmoplastic melanomas are 
characterised by the presence of atypical spindle cells separated by collagen 
fibres, occurring usually in individuals with chronic sun damage (Scolyer and 
Thompson, 2005). Also, mucosal melanomas that are also rare but usually 
diagnosed in an advance stage because of the location (inside nose, mouth, genital 
areas). 
 
1.2.3. Etiology and risk factors of melanoma 
 
Environmental, phenotypic and genetic factors interact in the development of 
melanoma. However, the exact etiology of malignant melanoma is quite complex 
and the molecular events directly related to melanoma progression are yet to be 
fully elucidated.  
 
1.2.3.1. Ultraviolet radiation  
 
Although it is a commonly accepted fact that solar radiation (natural or artificial) 
is a major environmental factor leading to melanoma, the evidence is not straight 
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forward. It is supported by the fact that the incidence and mortality among 
Caucasians is increasing proportionally with the intensity of the sun. In other 
words, the evident correlation between sun exposure and ethnic background is 
demonstrated by studies showing that people with fair skin living at low latitudes 
are more likely to develop a skin tumour than dark skinned-populations (Crombie, 
1979). 
Ultraviolet radiation is composed of UVA with a wavelength of (320-400nm), 
UVB (280-320nm) and UVC (100-280nm) that is completely blocked by the 
ozone layers and are therefore not involved in solar-induced carcinogenesis. 
Although UVB is partially filtered and only a minor amount of radiation reaches 
the earth, it has been demonstrated that it induces skin cancer. At a molecular 
level, UVB exposure increases DNA damage, inhibits antioxidants, and 
suppresses the immune system (Sauter and Herlyn 1998).  
The most frequent DNA photoproducts made by UV radiation are the results of 
joining adjacent cytosines or thymines resulting in the formation of pyrimidine 
dimers that can be cyclobutane-pyrimidine dimer or pyrimidine pyrimidone (4-6)  
photoproducts (Brash, 1997). Both photoproducts cause mutations and change the 
structure of DNA by insertion of adenine opposite the damaged cytosine during 
DNA replication, in about 70% of cases C is then replaced by T making CC to TT 
mutations that are distinctive feature of UV-induced mutations (Hutchinson, 
1994) (Figure 1.7). Such mutations are commonly associated with p53 
inactivation in BCC and SCC. However UV induced signature mutations as 
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described above are not observed in any known melanoma-associated tumour 
suppressor gene. 
Studies based on animal models have proven that UVB radiation suppresses 
immune reaction and induces tolerance to antigens. UVB is also known to induce 
DNA damage and upregulate gene expression through intracellular signal 
transduction pathways (Ichihashi et al., 2003).  
Although UVA is generally less carcinogenic than UVB, it is the major UV 
radiation that reaches the earth and can damage DNA directly and indirectly by 
generating oxidative stress. In addition, UVA can induce DNA strand breaks and 
chromosomes translocations by generating free oxygen radicals in the cell (de 
Gruijl, 1999). Also, intermittent repeated exposures to sunlight from childhood 
are epidemiologically shown to be major cause of melanoma. 
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Figure 1.7: UV radiation induces formation of cyclobutane pyrimidine dimers (linking 
carbons 5 and 6 of each pyrimidine) and 6-4 photoproducts (adjacent thymine or 
cytidine bases are photoactivated forming a 4-6 link) (Web Book Publishing, 2007). 
 
1.2.3.2. Oxidative damage 
 
Mutations caused by oxygen free radicals can alter the function of oncogenes, 
tumour suppressor genes and important house keeping genes and potentially 
leading to loss of cell cycle control and transformation of melanocytes (Hussein, 
2005).  
Cellular stresses induced for instance by DNA damage may activate the tumour 
suppressor gene P53 and cause accumulation of p53 in the nucleus which can lead 
to G1 cell cycle arrest. 
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The transition from G1 to S phase is controlled by p53, therefore cells with DNA 
damage will undergo a repair before progression to DNA replication in S-phase of 
the cell cycle. If the damage is not repaired, the cells may progress towards 
apoptosis or programmed cell death (Levine et al., 1994).  In non-melanoma skin 
cancer such as BCC and SCC, alterations in the P53 tumour suppressor gene are 
early events involved in the progression and are often point mutations that are 
UV-related such as CC-TT tandem base substitutions (Ziegler et al., 1994).  
 In melanomas, P53 gene mutations are rare and late events that occur during 
progression to a higher step of malignancy (Hussein et al., 2003). Despite the 
strong evidence of the implication of UV radiation in the initiation of BCC and 
SCC, the role of UV concerning the development of CMM is still unclear. 
 
1.2.3.3. Skin Type  
 
Besides environmental factors, endogenous factors play an important role in skin 
cancer development such as skin type (fair skin populations are more prone to 
develop skin cancer), genetic predisposition (familial melanoma) and immune 
deficient status.  
 
1.2.3.4. Familial predisposition 
 
The other significant risk factor for melanoma mentioned above is familial 
predisposition, which is described mostly by the inheritance of mutations in 
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highly-penetrant genes (Thompson et al., 2005). In
 
the majority of these families, 
the propensity for melanoma is
 
associated with the presence of abnormal 
melanocytic naevi,
 
the so-called atypical mole syndrome (AMS) phenotype 
(Newton, 1994). Familial predisposition for melanoma accounts for 
approximately 10% of the cases of melanoma (Greene and Fraumeni, 1979) and is 
believed to be associated with familial aggregation of dysplastic nevi (Dysplastic 
Nevus Syndrome DNS). However, studies based on inherited melanoma have 
been instrumental in leading to a better understanding of the genes involved in 
melanoma progression, by identifying the genetic alterations and cytogenetic 
losses involving many chromosomal regions.  
 
1.2.4. Development and pathogenesis of cutaneous malignant melanoma  
 
It is important to detect a melanoma at its early stages in order to maximise 
treatment options. Most melanoma cases can be diagnosed clinically by the 
recognition of the symptoms of the so-called ABCDE system which corresponds 
to: Asymmetry, Border irregularity, Color variation, Diameter and Elevation 
(Poole and Guerry, 2005). 
However, the prognosis of a patient diagnosed with melanoma depends on two 
factors: the thickness of the primary tumour and the presence or absence of 
metastasis to regional lymph nodes (Thompson et al., 2005). Therefore, the 
survival rate of the patient is closely linked to the stage of tumour development. In 
2002, a staging system was proposed by the American Joint Committee on Cancer 
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(AJCC 2002) estimating melanoma-survival rates at different stages as shown in 
Table 1.1: 
           Stages            Phase                             Survival Rates 
                                                                    5 years                          10 years 
               I                       RGP                      93%                                  85% 
              II                       RGP                      68%                                   55% 
             III                      VGP                       45%                                  36% 
             IV             VGP+metastasis             11%                                   6% 
 
Table 1.1: Melanoma-specific survival estimates, according to the 2002 AJCC system 
                     (Thompson et al.,2005). 
 
As shown in the table above, there are 4 melanoma stages corresponding to the 
tumour thickness and ulceration. Stages I and II represent the radial growth phase 
and the stages III and IV characterise the vertical growth phase. Also, the stage IV 
of a melanoma tumour is characterised by the metastatic phase which is the 
invasion or spread of the tumour to other sites of the body, mostly in visceral sites 
such as lung, liver, brain, bone and small intestine (Chin et al., 1998).  
Melanoma develops as a result of an accumulation of changes in the genetic 
pathway that controls the division and development of the melanocytes, these 
changes are the result of genetic alterations occurring in oncogenes, tumour 
suppressor genes or DNA repair genes. 
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There are a number of factors influencing the changes from a benign melanocyte 
to the proliferation into a melanoma. This initiation occurs at both molecular and 
chromosomal levels and can be applied to most cancer types. The diagram below 
(Figure 1.8) shows these various factors, the events can happen in an overlapping 
manner (like the growth and resistance to apoptosis) or can be extended in time 
(tumour initiation to invasion and metastasis).  
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Figure 1.8: Molecular pathogenesis of melanoma (adapted from Carlson et al.,     
2005). Various factors leading to the progression and development of cancer in 
general.  
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1.3. Molecular Genetics of Cutaneous Malignant Melanoma 
 
Recent advances in molecular biology have led us to a much better understanding 
of the biological events of skin cancer formation.  As it is the case for most 
cancers, RB, p53, and RAS pathways appear to play prominent roles in the 
pathogenesis of several skin cancer types (Tsai and Tsao, 2004). However, unlike 
most cancers, mutations affecting p53, the retinoblastoma gene product RB, 
PTEN are rare or relatively late events in melanoma progression (Carlson et al., 
2005).  
Although more than 90% of melanomas are sporadic rather then familial, several 
studies have been conducted on individuals with familial predisposition to 
melanoma in order to identify the genetic basis for melanoma susceptibility (Pho 
et al., 2006). In addition, the analysis of susceptibility genes in patients with 
dysplastic nevus syndrome (DNS) or multiple atypical naevi are strong markers 
for melanoma risk irrespective to family history (Thompson et al., 2005). 
Karyotype analysis and cytogenetics studies of melanoma have revealed genetic 
changes in different chromosomes which include: 
 1p, 6q, 9p, 10q and 11q. 
Consistent deletions and loss of heterozygosity (LOH) in 1p, 6q and 9p suggest 
the involvement of tumour suppressor genes in these regions (Smedley et al., 
2000). The genetic changes at these locations are discussed below and 
summarised in Table 1.2.  
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1.3.1. Chromosomal aberrations in melanoma  
 
 Chromosome 1 abnormalities in CMM 
 
Chromosome 1 aberrations are found in a number of various cancers including 
cutaneous melanoma. A study conducted by Goldstein and colleagues in 1993 on 
a set of 13 families with CMM and DN (dysplastic naevus) revealed a melanoma 
susceptibility locus on chromosome 1p36. Loss of heterozygosity has been 
located in the short arm of chromosome 1, in the region flanked by the 
Pronatrodilatin (PDN) and the anonymous marker (D1S47) using multipoint 
linkage analysis on 99 relatives of 6 families having cutaneous melanoma 
susceptibility (Bale et al., 1989).  
In addition, it was demonstrated that LOH at loci in the distal region of 1p appears 
to accumulate during tumour progression (Dracopoli et al., 1989). In other words, 
alterations in chromosome 1 arise late in tumour progression. The transfer of 
chromosome 1 into highly metastatic human malignant melanoma cell line 
suppressed metastasis without altering tumourigenicity (Miele et al., 1996). 
 
 Chromosome 6 abnormalities in CMM 
 
Trent et al., in 1989 presented in a report some of the various alterations of a 
recurring translocation site involving the long arm of chromosome 6 (6q) in 
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malignant melanoma and especially a translocation (t) between chromosomes 1 
and 6. 
Different studies have also shown that loss of genetic material on chromosome 6 
is   associated with the progression of human melanomas, and that the 
introduction of chromosome 6 into metastatic human melanoma cell lines 
suppresses metastasis without affecting the ability of the hybrids to form 
progressively growing tumours. This suggests the evidence of the presence of a 
tumour suppressor gene(s) on 6q (Goldberg et al., 2003).  
It has also been demonstrated that the deletions on 6q are related with the losses 
on 9p and 10q which suggests that 6q losses occur after initiation of 
tumourigenesis (Walker et al., 1995). 
 
 Chromosome 10 abnormalities in CMM 
 
A region on the long arm of chromosome 10 (10q24-26) has attracted substantial 
attention due to its involvement in a wide spectrum of human cancers (Chin et al., 
1998). Another study has suggested the fact that although segmental deletions are 
relatively rare, they have been useful in defining a common region of loss of 
heterozygosity and chromosomal rearrangements spanning 10q24-27 (Robertson 
et al., 1998).  
The region 10q23 is also deleted or mutated in a wide range of advanced tumours 
including melanoma. It has been identified that alterations in the tumour 
suppressor gene PTEN/MMAC1 (Phosphatase and Tensin/Mutated in Multiple 
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Advanced Cancers 1)  occur in some metastatic melanomas, and that mutations of 
this gene plays a role in the progression of some forms of melanoma (Celebi et 
al., 2000). 
 
 Chromosome 11 abnormalities in CMM 
 
In 1996, a report published by Tomlinson and colleagues suggested that multiple 
melanoma tumour suppressor genes may exist on chromosome 11, and also play a 
role in other types of cancer. 
Cytogenetic analysis of a number of patients with regional or disseminated 
melanoma provides the evidence of chromosomal breakpoints at 11q23-ter 
(Thompson et al., 1995). 
The aim of a study conducted by Utikal and associates in 2005 was to evaluate 
cytogenetic aberrations of the gene cyclin D 1(CD1) locus at chromosome 11q13 
in cutaneous malignant melanoma. Cyclin D1 is associated with progression 
through G1 and entry into S phase of the cell cycle, and acts as a partner of cyclin-
dependent kinases (CDKs). The results obtained have suggested that cyclin D1 
could well be involved in the pathogenesis of a subset of malignant melanoma. 
Also, results suggested that CD1 may be an oncogene in melanoma and that 
targeting the expression of this gene can have beneficial effect in therapeutic 
treatment for melanoma (Sauter et al., 2002). Additional studies will have to 
elucidate the role of further genes located at chromosome 11q13. 
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Table 1.2 is a summary of some of the chromosomal rearrangements that occur at 
different locations. The chromosomal changes in 9p and 10q are generally early 
events in the melanoma progression. The alterations detected in 1p and 6q occur 
after the initiation of melanoma tumourigenesis and are considered as later events. 
 
 
 
Chr              Mutations                                Regions            LOH                     References 
 
1            Deletions, Breakpoints, LOH                 1p36; 1p22-q21            22%                              Bale et al., 1989 
                                                                                                                                                     Dracopoli et al., 1989 
                                                                                                                                                         Walker et al., 1995 
 
6             Deletions, translocations,                     6q22-27                   30%                            Trent et al., 1989  
                    6p isoforms, LOH                                                                                                      Cowan et al., 1986                                                                                    
                                                                                                                                          Walker et al., 1995 
 
9            LOH, deletions, recombinations                9p21                    50-60%                             Hussein 2004 
                                                                                                                                                         Walker et al., 1995 
           
10         LOH, chromosomes rearrangements             10q24-26                  32%                   Robertson et al., 1998      
                                                                                                                  Walker et al., 1995 
 
11       Deletions, loss of chromosome, LOH              11q23-ter                25%                    Thompson et al., 1995 
                                                                                                              Robertson et al., 1996b 
                                                                                                                                                       Walker et al., 1995 
 
Table 1.2:    Chromosomal aberrations in cutaneous malignant melanoma. 
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1.3.2. Melanoma and the 9p21 region  
  
Carcinogenesis is the combined effect of the inactivation of tumour suppressor 
genes and activation of oncogenes. The inactivation of TSGs happens either by 
acquiring somatic mutations or by the presence of inherited mutations. Based on 
the two hit hypothesis, the inactivation of TSGs requires two genetic events to 
inactivate both alleles of the gene. Evidence of the presence of TSGs can be 
obtained from tumour loss of heterozygosity (LOH) studies, which can be the 
result of chromosomal deletions, mitotic recombination, non-disjunction, or 
unbalanced translocation (Hussein, 2004). 
Loss of heterozygosity studies have revealed the existence of tumour suppressor 
gene(s) in chromosome 9. Several studies of cytogenetics, linkage, and molecular 
analyses of familial and sporadic melanomas provided strong evidence that loss of 
a tumour suppressor residing at 9p21 represents a critical step in the development 
of almost all melanomas (Chin et al., 1998). The INK4A locus on 9p21 encodes 
for the best-characterised high-penetrance gene p16. In addition, various studies 
have demonstrated that some of the genes implicated in cutaneous malignant 
melanoma map to 9p21 which include p14
ARF
, p16 (CDKN2A/MTS1/INK4A) 
and p15 (CDKN2B, MTS2/INK4B) (Haber, 1997) (Figure 1.9). The INK4 locus 
encodes two distinct tumour suppressor proteins: p16 composed of exon 1α, 2 and 
3, and p14
ARF  
which is a product of an alternatively spliced transcript with coding 
regions composed of exons 1β and 2 (Pho et al., 2006). Also, The p15 (INK4b) 
Chapter 1: Introduction             
 
       Page 26
   
 
gene is located adjacent to p16 (INK4a) on 9p21 and is codeleted in a high 
proportion of established human cancer cell lines (Kamb et al., 1994). 
The p16 gene is deleted or mutated in more than half of cell lines derived from 
sporadic melanoma tumours (Kamb et al., 1994; Kumar et al., 1998). Germline 
mutations for the p16
INK4a
 gene are found in about 25% of families with 
inheritable melanoma (Carlson et al., 2005). In addition to mutations and LOH, 
promoter methylation is a common mechanism of silencing p16 gene activity in 
sporadic melanoma (Carlson et al., 2005). 
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A 
 
 
B 
 
 
 
Figure 1.9: A: The INK4 locus in chromosomal region 9p21. The INK4 contains two 
genes: CDKN2A encodes for two transcripts p16 (Exons 1α, 2 and 3) and p14ARF (exon 
1β, 2 containing an alternative reading frame, and exon 3 untranslated coloured in blue). 
The other gene is CDKN2B that encodes for p15 composed from exon1 and 2 represented 
here in light blue boxes (Adapted from Haber, 1997). B: schematic view of the CDKN2A 
and CDKN2B genes (in green) showing exons (in blue) sizes and intronic distances using 
the NCBI sequence view.  
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Cell cycle control is dependent on complex interaction between cyclins, cyclin-
dependent kinases and cyclin-dependent kinase inhibitors.  
The cyclin-dependent kinases (CDKs) are enzymes that regulate a number of 
target molecules by phosphorylation, which will lead to DNA replication and 
mitosis. The CDKs are activated by a group of positive regulators called cyclins 
and inhibited by the proteins: p15, p16, p21 and p27 (Kamb et al., 1995).  
The complex action of CDKs and cyclins phosphorylates the Retinoblastoma RB 
gene (13q14). Phosphorylation of RB occurs through the action of cyclin 
D1/CDK4-6 in early G1 phase of the cell cycle, by cyclin E/CDK2 in late G1 and 
early S, and by cyclin A/CDK2 in S phase. At its unphosphorylated state, Rb does 
not act directly to control transcription but it interacts with the transcription factor 
E2F, inhibiting transcription and suppressing cell growth. However, 
phosphorylated RB (pRB) by the complex cyclin/CDK action does not bind to 
E2F allowing the initiation of the transcription (Figure 1.10). When p16 is 
defective, it is unable to inactivate CDK4 and CDK6, which phosphorylates Rb, 
releasing the transcription factor E2F and leading to the cell cycle progression 
(Serrano, 1997).  
The alternative product of the gene CDKN2A p14
ARF 
has been implicated in 
melanoma however strong evidence is lacking. One of the identified functions of 
p14
ARF 
is stabilising p53 through inhibition of MDM2 activity, although p53-
independent activities of p14
ARF
 and can be upregulated by oncogenes such as 
RAS and MYC (Lowe and Sherr, 2003). In addition, Robertson and Jones (1998) 
have proposed the existence of an autoregulatory feedback loop which allows 
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tight control over the levels of p53 in normal cells. In other words, ARF is 
considered as a critical element of the p53 pathway, and it increases the level of 
functional p53 through interaction with the proto-oncogene MDM2 leading to 
apoptosis and cell cycle arrest Robertson and Jones (1998). 
 
Figure 1.10: Cell cycle. The association of the cyclins and the cyclin-dependent kinases 
phosphoraylates the protein Rb. Phosphorylated pRB doesn not interact with E2F, 
therefore it will induce the transcription resulting into the progression from G1 to S 
phase. The INK4 family of tumour suppressor genes p15, p16, and p18 inhibits the 
interaction of cyclins/CDK, RB remains unphosphorylated and interacts with E2F, and 
consequently the cell cycle is arrested at G1/S. (Adapted from MacDonald and Ford, 
1997). 
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1.3.3. Melanoma susceptibility genes 
 
The literature suggests that a number of genes are involved in the predisposition 
to melanoma. Studies conducted on a proportion of familial melanoma cases have 
demonstrated the existence of high-penetrance genes (conferring a high-risk of 
developing CMM) and low-penetrance genes (conferring a low-risk of developing 
CMM).  
 
1.3.3.1. High-penetrance susceptibility genes: 
 
CDKN2A 
 
CDKN2A (cyclin-dependent kinase inhibitor 2A) was the first melanoma 
susceptibility gene to be identified (Kamb et al., 1994) and it codes for two 
unrelated proteins known as p16 and p14ARF (alternative reading frame). P16 
acts as a tumour suppressor by arresting cells at the G1 phase, ultimately leading 
to the negative regulation of cell growth. More specifically, p16 inhibits the 
activity of the cyclin D1 complex by preventing its interaction with cyclin-
dependent kinase 4 (CDK4) or CDK6. Allowing cyclin D1 to interact with CDK4 
or 6 results in the phosphorylation of the retinoblastoma protein (Rb) (leading to 
cell cycle progression beyond the G1 phase). However, since p16 blocks these 
interactions, it is able to act as a tumour suppressor. P14ARF on the other hand 
behaves as a tumour suppressor by enhancing apoptosis and blocking oncogenic 
Chapter 1: Introduction             
 
       Page 31
   
 
transformation. Both of these proteins act on the Rb and p53 pathways; two 
critically important pathways underlying cell cycle control.  
Although CDKN2A is an important melanoma susceptibility gene, the incidence 
of germline CDKN2A mutations in the general population is remarkably low 
(Hayward, 2003). Furthermore, the occurrence of CDKN2A mutations in familial 
cases is only 20-40% (Hayward, 2000), which suggests the possible involvement 
of other candidate genes that may be implicated in melanoma.  
 
CDK4 
 
The cyclin dependent kinase 4 gene is an oncogene located in 12q13 and encodes 
for the CDK 4 which is one of the targets of p16.  Although few cases of CDK4 
mutations have been reported, familial melanoma studies have demonstrated 
mutations in codon 24: R24C (Arginine to Cysteine) and R24H (Arginine to 
Histidine) changes (Zuo et al., 1996; Soufir et al., 1998), these changes occur 
exclusively at the binding domain; the arginine normally present at this location is 
important for the binding of p16. Therefore, these mutations induce the loss of 
cell-cycle regulation downstream of p16.  
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1.3.3.2. Low-penetrance susceptibility genes: 
 
MC1R 
 
The Melanocortin-1 receptor gene, located on 16q24, is the most common low-
penetrance melanoma-susceptibility gene so far identified. MC1R codes for the 
receptor of α-melanocyte stimulating hormone (α-MSH), the binding of α-MSH 
and MC1R results in the stimulation of production of eumelanin (brown/black 
pigments over pheomelanin (red/yellow pigments) (Suzuki et al., 1999).  
MC1R is involved in the pigmentation pathway, and therefore appears to play a 
key role in hair colour, skin type and response of the skin to tanning. 
In 1995, Valverde and colleagues have shown that MC1R is highly polymorphic, 
and reported the presence of variants for this gene in humans. It appears that there 
are more then 20 allelic variants and some are associated with increased 
melanoma susceptibility because they change skin pigmentation and tanning 
ability. Three particular variants of MC1R are associated with red hair and fair 
skin [R151C (Arginine to Cysteine), R160W (Arginine to Tryptophan), D294H 
(Aspartic acid to Histidine)] (Box et al., 1997).  
Other melanoma susceptibility loci have been mapped, although the putative 
causal genes at these loci have yet to be identified (Fargnoli et al., 2006). Some of 
these loci are: CDKN2A polymorphisms, EGF (epidermal growth factor gene), 
GSTM1 (glutathione S-transferase gene), CYP2D6 (cytochrome P450 
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debrisoquine hydrolase locus), VDR (vitamin D receptor gene) (reviewed in 
Hayward, 2003).  
 
1.3.4. Pathways involved in melanoma  
    
The transformation of a normal melanocyte to a malignancy results from an 
abnormal proliferation of the cells that have lost cycle regulation mechanisms.  
Oncogenes and tumour suppressor genes control the regulation of the cell cycle 
via a number of interactions between the proteins in the form of 
activation/inhibition pathways. There are two major cell cycle regulatory 
pathways that are altered in melanoma, the RAF-MAPK pathway and Pi3K-Akt 
pathway which involve the retinoblastoma (Rb) and p53 tumour suppressor gene.  
An extensive knowledge of cell cycle regulatory mechanisms will increase the 
understanding of the process by which a normal cell develops into a malignancy 
(Li et al., 2006). The mammalian RAS gene family consists of three members 
which are located on different chromosomes: H-RAS and K-RAS genes are the 
cellular counterparts of the viral Harvey and Kirsten genes, respectively, and the 
N-RAS gene is derived from a human neuroblastoma cell line (Bar-Sagi, 2001). 
The RAS genes are signal transducers frequently mutated in human cancers. 
Recent studies have estimated that 10-20% of the RAS gene family, and more 
specifically NRAS, are mutated in human melanoma (Gorden et al., 2003). 
Alterations of oncogenic RAS activate both the PI3K and RAF cascades which 
have been strongly associated with melanoma development. The frequent loss of 
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the tumour suppressor gene PTEN (Phosphatase and TENsin homolog) in 
melanocytic lesions is evidence of the involvement of PI3K-Akt pathway in the 
progression of the malignancy. LOH in chromosome 10q has been extensively 
studied and found to account for 30-50% of melanoma (Herbst et al., 1994). 
PTEN has both lipid phosphatase and protein phosphatase activities that inhibit 
Akt activation by PI3K. The Akt protein, when phosphorylated, acts mainly as an 
antagonist of apoptosis (Haluska et al., 2006).  
In other words, PTEN reduces PIP3 level (Phosphatidylinositol tri-phosphate) and 
acts downstream on serine/threonine Akt by decreasing its activity, therefore 
PTEN is a negative regulator of the PI3K-AKT pathway. Inactivation of PTEN 
results in the hyperphosphorylation of Akt which increases cell proliferation and 
enhances resistance to apoptosis (Wu et al., 2003). 
However, it is not yet clear whether PTEN loss of activity occurs at an early or 
late stage in melanoma progression.  
 The role of RAF-MEK-ERK pathway in melanoma progression has been the 
main focus of several studies in the past years, especially after the identification of 
BRAF gene mutations in a number of melanomas. In fact, mutations of BRAF 
gene have been estimated at 67% by Davies and colleagues in 2002. The most 
frequent mutation in the BRAF gene is V599E, and occurs at the BRAF kinase 
domain which leads to elevated protein activity and results in increasing 
activation of ERK. Activation of the RAF-MEK-ERK pathway is a critical 
component of tumour cell proliferation and survival in general (Gordon et al., 
2003). In addition to the high rate of BRAF mutations (approximately 70%), 
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expression of Brn-2 POU domain transcription factor has been shown to be high 
in melanoma cell lines but not in melanocytes resulting in increased proliferation 
(Eisen et al., 1995). It has been found that high levels of Brn-2 expression might 
be triggered by activation of the MAP kinase cascade arising from mutations in 
the BRAF gene resulting in increased proliferation (Goodall et al., 2004). 
 
Gene type Gene Frequency Type of modification 
 
Oncogenes 
BRAF 70% Substitution (V599E) 
NRAS 10-20% Mutation (codon61) 
 
Tumour suppressor genes 
CDKN2A 30-70% Deletion, silencing, mutation 
PTEN 20-40% Deletion, mutation 
P53 10% Loss, mutation 
 
Table 1.3:  Summary of main genetic alterations in cutaneous malignant melanoma. 
 
 1.3.5. Epigenetic events in melanoma  
 
Modifications in DNA methylation are regarded as epigenetic events rather than 
genetic changes because they do not alter the genetic code. Recent studies have 
demonstrated the existence of a strong correlation between methylation alterations 
and transcriptional inactivation. In addition, genetic alterations as well as 
epigenetic events can contribute to the carcinogenic process (Strathdee, 2002). 
DNA methylation occurs at the position 5 of cytosine residues in the pyrimidine 
ring of CpG dinucleotides (Cytosine-phosphate-Guanine sites) by the covalent 
addition of a methyl group (-CH3) by DNA methyltransferases (Figure 1.11). CpG 
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islands are regions of DNA that contain high percentage of CG nucleotides and 
are commonly found near the promoter region of the genes. DNA methylation has 
been reported to regulate gene expression by transcriptional silencing when 
occurring at CpG islands (Razin and Riggs, 1980).  
Methylation of CpG rich sequences of the promoter region of the genes and the 
role that epigenetic events play in the development of various cancers have 
recently become an important area of investigation in assessing the mechanisms 
of tumour suppressor and regulatory gene inactivation (Hoon et al., 2003) and are 
at least as important as the inactivation of tumour suppressor genes and activation 
of oncogenes in the progression of cancer (Jones and Baylin, 2002).   
In normal somatic cells, CpG islands are usually unmethylated in the promoter 
regions of tumour suppressor genes. However during cancer progression there is 
an aberrant hypermethylation of these regions which lead to effective transcription 
silencing of the selected tumour suppressor genes (Robertson, 2005). 
 
Figure 1.11:  A promoter region showing methylated CpG islands which results 
in transcriptional silencing of several target genes such as p16, p14, MTAP, Apaf-
1 for melanoma. 
Chapter 1: Introduction             
 
       Page 37
   
 
Studies of malignant melanoma have revealed that at least 50 genes have been 
identified to be silenced by promoter hypermethylation during disease 
development and progression (Gallagher et al., 2005; van der Velden et al., 2003).  
The most well known gene involved in the progression of melanoma is CDKN2A 
tumour suppressor which has been shown to be regulated via chromosomal 
deletions of the 9p21 region, inactivating mutations and also by promoter 
hypermethylation (van der Velden et al., 2001).  
Van der Velden and colleagues showed in 2001, that the p16 promoter was 
hypermethylated in 50% of uveal melanoma cell lines and 32% of primary uveal 
melanomas. Moreover, another study reported the loss of p16 protein expression 
by hypermethylation of the CDKN2A gene promoter in 19% of primary 
cutaneous melanomas and 33% of metastases derived from melanoma (Straume et 
al., 2002).  
Another tumour suppressor gene MTAP (Methylthioadenosine phosphorylase) 
has been demonstrated to carry a homozygous deletion in only one out of nine 
melanoma cell lines and all others showed a reduction of MTAP expression due to 
promoter hypermethylation of MTAP gene (Behrmann et al., 2003). In addition, 
the same study demonstrated the existence of an inverse correlation between 
MTAP protein levels and tumour progression: MTAP expression decreased from 
benign melanocytic nevi to primary melanoma and to metastatic melanoma in 
vivo. In a same manner, another important tumour suppressor whose expression is 
negatively correlated with the development of malignant melanoma is Apaf-1 
Chapter 1: Introduction             
 
       Page 38
   
 
which is a cell death effector that mediates p53-dependent apoptosis (Soengas et 
al., 2001).  
The use of methylation inhibitors or demethylating agents such as 5-azacytidine 
and its derivative 5-aza-2‟-deoxycytidine (5Aza-dC) has been a useful tool to 
demonstrate the gain of expression of target genes that have been silenced by 
DNA methylation in the promoter regions. Azacytidine is incorporated in the 
DNA during replication and inhibits methyltransferase activity because the 
enzyme becomes irreversibly bound to the azacytidine residues into the DNA 
(Christman, 2002).   
Following treatment with (5Aza-dC), mRNA transcripts could be re-expressed in 
melanoma cell lines having hypermethylated genes (Hoon et al., 2004). These 
agents have been used as potential chemotherapeutics agents for cancer because 
of their ability to restore gene function to treated cells in culture and patients with 
malignant diseases (Cihak, 1974). In a study conducted by Muthusamy et al. 
(2006), 17 genes have been screened in a microarray-based assay showing a re-
expression following treatment with 5AzadC. Similar results for the gene MTAP 
re-expression have been demonstrated after exposure to 5-azacytidine in 
combination with interferon-γ (Rothhammer and Bosserhoff, 2007).  
 
 
 
 
 
Chapter 1: Introduction             
 
       Page 39
   
 
1.4. Treatment of cutaneous malignant melanoma 
 
1.4.1. Surgical excision  
 
The current treatment options for melanoma are surgical excision, which is the 
first step of treatment. This surgery depends on the tumour thickness and stage of 
progression of the disease, melanoma in situ or stage I and II are usually treated 
with surgical removal of the lesion and surrounding tissues (margins), and can 
also cure stage III melanoma if the lymph nodes are removed. However, once the 
tumour has spread from the skin to distant organs, it is unlikely to be curable with 
surgical excision.  
Regional recurrence has been associated with the excision margin, as studies have 
demonstrated that a 1-cm margin of excision of a tumour of 2 mm thickness is 
associated with a significant greater risk of regional recurrence than an excision of 
3-cm margin; however the survival rate is similar (Thomas et al., 2004).  
In most of cases, further treatment is not needed after surgical excision especially 
for the early melanomas, since the recovery of the patients is assumed. However, 
in some cases recurrence of melanoma can occur by appearance of a lesion beside 
the site of the original one or it may appear in the lymph node draining that area, 
also the local
 
recurrence rate is significantly affected by the thickness of the 
primary
 
lesion and the presence or not of ulceration (Karakousis et al., 1996).  
Many agents have been investigated for treatment of melanoma, but few have 
Chapter 1: Introduction             
 
       Page 40
   
 
shown promising results. In addition, attempts to improve survival after treatment 
require considerable effort since some therapies have failed to be successful.   
 
1.4.2. Adjuvant therapy  
 
However, early detection and appropriate treatment such as adjuvant therapy have 
improved outcomes (Hamm et al., 2007). Adjuvant therapy is the treatment given 
after surgery and is either chemotherapy or radiotherapy; the purpose of this 
therapy is to destroy remaining cancer cells after the surgery.  
Systemic chemotherapy applied for melanoma cases consists on use of anticancer 
drugs that can be single agent or multi-drug combinations. The main drug used for 
treatment of melanoma is Dacarbazine (DTIC) that demonstrated an overall 
response rate of 6.8-12.1% (Middleton et al., 2000). This drug can be combined to 
other agents such as carmustine, cisplatin and tamoxifen (Dartmouth regimen) but 
no proof has been provided yet that multi agent chemotherapy is superior to 
single-agent DTIC chemotherapy (Lee et al., 1995). Temozolomide is another 
agent that has an equivalent efficacy to that of DTIC and is for patients with 
advanced metastatic melanoma (Middleton et al., 2000).  
 
1.4.3. Immunotherapy 
 
In addition, chemotherapy drugs can be combined to immunotherapies including 
interferon alpha (IFN) and interleukin-2 (IL-2). Cancer immunotherapy stimulates 
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the patient‟s immune system to recognize and destroy cancer cells more 
efficiently.  IL-2 is a cytokine that plays an important role in T cell activation and 
its anti-tumour activity has been demonstrated in a number of murine tumour 
models (Rosenberg et al., 1985). Data from various trials have shown that single 
agent IL-2 given in high doses had response rates of 10-20% (Atkins et al., 1999). 
The latter techniques used for immunotherapy of melanoma use two types of 
immune cells in combination with IL-2: lymphokine-activated killer (LAK) and 
tumour-infiltrating lymphocytes (TIL). However, randomised studies have shown 
that there is no superiority for IL-2 with LAK cells therapy compared to single-
agent IL-2 therapy (Tarhini and Agarwala, 2006).  
Interferon alpha 2b (IFN-α) is commonly used as a treatment for patients who are 
at a high risk of recurrence of melanoma, also for adjuvant therapy after surgical 
removal of the tumour. This immunotherapeutic agent is a cytokine exhibiting a 
potential anti-tumour effect and is used mainly in phase II and III melanoma 
patients. Trials using IFN-α as an adjuvant therapy have shown an improvement 
of overall disease-free survival (from 2.8 to 3.8 years) (Kirkwood et al., 1996). 
However, trials of single-agent IFN have demonstrated disappointing results and 
the same concerning combination of IFN and DTIC (Hamm et al., 2007). In 
addition, IFN displays a significant toxicity as 25% of patients show moderate to 
severe flu-like symptoms after completion of IFN therapy (Kim et al., 2002).  
Studies have shown that UV radiation is immune suppressive. In other words, the 
immune suppressive effects acquired from exposure to UV radiation contribute to 
skin cancer development by depressing cell-mediated immune reactions that 
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normally serve to destroy the developing skin tumours (Kripke, 1974; Kripke and 
Fisher, 1976). Highly antigenic properties of UV-induced tumours were identified 
by the growth of these tumours after transplantation in immune suppressed 
recipient mice while they were recognised and rejected in normal immune system 
(Kripke, 1974).   
Findings of several studies have supported the hypothesis that UV radiation was 
having two effects: immune suppression and induction of skin cancer, for instance 
immune suppressed transplant patients have a high risk of developing skin cancer 
(Penn, 2000). Therefore, it is clear that there is an association between UV-
induced immune suppression and carcinogenesis, and it is critical to identify the 
mechanisms that suppress immunologic reactions after solar stimulation (Ullrich, 
2005). Furthermore, a novel treatment has been developed targeting melanoma-
associated antigens (MAA) which are highly immunogenic human antigen that are 
recognised by cytotoxic T lymphocytes. Downregulation of MAA is one of the 
mechanisms that aids in evasion of immune surveillance, (van Dinten et al., 
2005).   
 
1.4.4. Vaccine therapy 
 
Development of vaccines to treat cancer has attracted a lot of attention especially 
with the success of vaccines against infectious diseases. But the difference is that 
cancer vaccines are therapeutic rather than prophylactic and are administered after 
the occurrence of the disease (Morton and Barth, 1996). In addition in the case of 
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cancer vaccines, the immune response requires between 12 to 14 weeks and 
induction of regression requires 6 to months compared to chemotherapeutic agents 
that induce a regression after 2 to 4 weeks because of their high cytotoxicity 
(Morton et al., 1992). 
Various vaccine strategies are being tested in patients with stage III or stage IV 
melanoma but have not yet been able to demonstrate a reliable clinical tumour 
regression and a proven efficacy (Terando et al., 2007).  
A number of clinical trials are currently being carried out using new agents that 
can possibly provide a more effective therapy for cutaneous malignant melanoma 
such as developing molecular therapy targeting the Ras-MAPK and PI3K/AKT 
signal transduction pathways, the proteasome, histone deacetylases, 
methyltransferases, and melanoma-induced angiogenesis (Becker et al., 2006). 
A recent clinical trial of Hodi et al 2008 of the drug imatinib mesylate (Gleevec) 
which targets Kit gene, showed major response of the drug in KIT-mutated 
melanoma. The same group reported that treatment using Gleevec has also forced 
metastatic melanoma into remission for the first time.  
 
1.5. Multistep melanoma tumourigenesis model  
 
The clinical, histopathological and biological aspects of cutaneous malignant 
melanoma and its progression are well recognized. However, the molecular 
aspects and the exact genetic events involved in the proliferation of melanoma are 
yet to be identified and understood.  
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The genetic analysis of malignant melanoma has shown that the progression into a 
metastatic tumour starts from the transformation of the melanocytes. This 
progression is controlled by the accumulation of genetic alterations as shown in 
the figure below.  
A model published by Hussein (2004), has proposed to divide the process of 
melanoma tumourigenesis into a multi-step genetic model. The progression 
consists in lesional steps from benign naevi to metastatic malignancy. 
Multistep tumourigenesis involves the inactivation of TSGs activation of 
oncogenes and defect in mismatch repair (MMR) genes. These events are poorly 
understood in melanoma proliferation. However, strong evidence has been 
provided about the implication of allelic alterations at several chromosomes in the 
development of cutaneous malignant melanoma and the transformation of 
melanocytes to a malignant phenotype (Fountain et al., 1990). Recent findings 
have revealed that melanoma tumourigenesis is a very complex process that 
involves allelic loss, microsatellite instability, and alterations of TSGs, mismatch 
repair proteins, oncogenes, and some growth factors (Hussein, 2004) (Figure 
1.12). Furthermore, tumour progression markers have been identified such as 
integrins are transmembrane glycoproteins cell surface receptors that mediate 
adhesion between the cell membrane and the extracellular matrix (Buck and 
Horwitz, 1987). Certain classes of integrin expression have been shown to be 
upregulated during transition from radial to vertical growth phase in melanoma. In 
particular, integrin αVβ3 has been identified as a tumour progression marker and 
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the increase in its expression correlates with the conversion of melanoma growth 
from radial to vertical (Seftor, 1998).  
 
 
 
 
 
Figure 1.12: Multistep melanoma tumourigenesis model. Accumulation of LOH 
and genetic instability from benign nevi to metastatic melanoma and inactivation of TSGs 
and activation of oncogenes, also effect from UV radiation.  
RGP: Radial Growth Phase. VGP: Vertical Growth Phase. MSI: Microsatellite Instability.  
MMR: Mismatch repair.  
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1.6. Research aim and objectives  
 
The efforts undertaken by various research groups in order to identify the 
molecular events leading to cutaneous malignant melanoma have resulted in the 
understanding of some of the mechanisms such as abrogation of TSGs, activation 
of oncogenes and accumulation of genetic changes, however, a clear picture is yet 
to be elucidated. The implication of the 9p21 region in CMM has been well 
documented and the CDKN2A locus has been demonstrated to carry homozygous 
deletions in various types of cancers. In addition to harbouring p16, other loci 
important to CMM progression appear to be located in the 9p21 region.  
Functional evidence of the presence of tumour suppressor gene(s) that functions 
independently of CDKN2A locus has been provided by Parris and colleagues in 
1999. These findings were later on supported by Pollock et al in 2001 who 
demonstrated LOH on the region 9p21 leaving CDKN2A intact.  
Hence, the aim of this project is to identify and characterise potential novel 
tumour suppressor gene(s) involved in the pathogenesis of cutaneous malignant 
melanoma. In doing so, we have set a number of objectives that were achieved 
during this work. First of all, constructing several monochromosome hybrids 
using microcell mediated chromosome transfer, and evaluate their 
tumourigenicity by soft agar assays. Then, carry out an expression analysis of the 
genes in the 9p21 region by RT-PCR. Potential candidate TSGs were then 
carefully evaluated by generating expression profiles via conducting quantitative 
real time PCR. 
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                                       CHAPTER 2 
CHAPTER 2: LITERATURE REVIEW 
GENERAL MATERIALS AND METHODS 
2.1. Cell lines 
 
UACC-903: Highly tumourigenic human malignant melanoma cell line carrying 
deletions in the exons 1α and 2, therefore generating inactive p16 and p14 
proteins (Trent et al., 1990).  
A9HyTK9: Mouse fibroblasts containing human chromosome 9 used as donors 
for MMCT (Cuthert et al., 1995). 
1BR3: Normal human fibroblasts (ECACC European Collection of Cell Culture, 
Arlett et al., 1988). Although there is no published record of p14 and p16 
mutations in this cell line, the status of this locus is presumed normal. 
 PC-3: Human prostate, adenocarcinoma (ECACC European Collection of Cell 
Culture, Ohnuki et al., 1980)  
PB-1: Provided by Prof Robert Newbold (Institute of Cancer Genetics and 
Pharmacogenomics, Brunel University UK) Human breast cancer cells. 21NTs 
transfected with hTERT. Other melanoma cell lines have been used for routine 
tissue culture work:  SK-MEL5, MEL-154, MRI-H-221 and HS695T.  
There was no published evidence of mutations in p16 and p14 genes in all other 
cell lines used in this work. 
 
2 
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2.2. Cell Culture 
 
The cell lines were routinely cultured in a Holten LaminAir Class II Haeraus 
Instruments hood. The human malignant melanoma cell line UACC-903 (a kind 
gift from Dr J.M.Trent, NIH, Bethesda, MD, USA (Trent et al., 1990) was used as 
a recipient during microcell mediated chromosome transfer (MMCT). This cell 
line is highly tumourigenic and has been chosen in several studies in order to 
identify tumour suppressor genes in malignant melanoma (Trent et al., 1990; 
Robertson et al., 1996).  
The UACC-903 cells were normally cultured in Dulbecco‟s Modified Eagle‟s 
Medium (DMEM) supplemented with 10% Newborn Calf Serum (NCS) both 
from Gibco, Invitrogen (Paisley, Scotland), 2 mM of L-Glutamine and 100 μg/ml 
of Penicillin and 100 μg/ml of Streptomycin (Gibco) in a humidified incubator at 
37°C and 10% CO2  (Heraeus 6000,  Heraeus Instruments, Hanau, Germany). The 
cells were grown as a monolayer and were confluent after 48 to 72 hours. Sub-
culture of UACC-903 cells consisted in splitting the cells 1:4 or 1:5 into 15 ml of 
complete DMEM for each Petri dish. After washing the monolayer with 10 ml 
versene (0.2mg/ml EDTA in PBS (Sigma, UK)), the cells were detached by 
incubation in 1 ml of  Trypsin (Gibco, Scotland) for few minutes and by tapping 
the dish gently or retropipetting few times.  
The cell suspension was put in a 15 ml tube after adding 9 ml of medium to 
neutralise the trypsin, and was centrifuged for 4 minutes at 1200 x g using a 
megafuge (Heraeus 1.0, Heraeus Instruments). 
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2.3. Cell lines storage and recovery from cryopreservation 
 
After checking the cultures using an inverted microscope (Olympus Europa 
GmbH, Hamburg, Germany) to assess the degree of cell density and confirm the 
absence of bacterial and fungal contaminants, the cells were stored in nitrogen 
liquid, after washing the monolayer with versene, and trypsinise with 1ml of 
Trypsin/EDTA. After centrifugation, the cells were resuspended in an appropriate 
volume of 70% medium, 20% NCS (Newborn Calf Serum, Gibco, Scotland), and 
10% of the cryoprotectant DMSO (DimethylSulfoxide) (Sigma, UK). 
 
2.4. Testing cells for Mycoplasma contamination 
 
Cells in culture were screened for mycoplasma contamination using two different 
methods. One adapted from Hoechst method, 2x10
5
 cells were plated onto a  
40 mm x 24mm coverslip in a 10 cm Petri dish and incubated at 37°C and 10% 
CO2. After 48 hours, the cells were washed in PBS (Phosphate Buffered Saline, 
Sigma, UK), then fixed onto the coverslips with freshly made 3:1 100% methanol 
to glacial acetic acid (Carnoy‟s fixative) for 5 minutes. Cells were washed three 
times in PBS and then briefly air dried. The coverslips were treated with Hoechst 
33258 stain (Sigma, UK) at 20 ng/ml in PBS and incubated at room temperature 
for 5 minutes in the dark, then rinsed again 3 times with PBS. After that the 
coverslips were placed inverted onto microscope slides for viewing by 
fluorescence microscopy. 
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The second method utilises PCR technology (see section 2.7) for the detection of 
mycoplasma in cell cultures. It consists in two PCR rounds, for the first PCR a 
reaction mix of 20 μl was prepared using 1 μl of 100-150 ng of DNA, 1 μl of 
forward primer GPO1 (5‟ ACTCCTACGGGAGGCAGCAGTA 3‟) at a 
concentration of 4 μM, 1 μl of reverse primer MGSO (5‟ 
TGCACCATCTGTCACTCTGTTAACCTC 3‟) at a concentration of 4 μM and 
17 μl of ReddyMix mastermix (Thermo Scientific Abgene, UK). The reaction 
conditions were 95°C for 30 seconds then 35 cycles at 95°C for 30 sec, 55°C for 
30 sec, 72°C for 1 minute. For the second PCR round, the same conditions were 
used except the used of the forward primer GPO2 (5‟ 
CTTAAAGCAATTGACGGGAACCCG 3‟). The PCR products of both rounds 
were visualised by electrophoresis on a 1.5 % agarose gel stained with ethidium 
bromide. A strong positive sample gives two bands, one at 720 bp from the first 
round and the other at 145 bp from the second round and a weak positive sample 
gives a single band at 145 bp showing the absence of mycoplasma contamination. 
All cells were found to be free of mycoplasma using both methodologies.  
 
2.5. Isolation of Genomic DNA 
 
Genomic DNA was isolated from tissue culture cells using Wizard
®
 Genomic 
DNA Purification Kit (Promega, UK). Initially, a confluent cell monolayer 
adherent in a 10 cm plate was trypsinised and harvested in a 15 ml centrifuge tube 
(Nunclon, Fisher scientific, UK). The cell pellet was resuspended in 1 ml of PBS 
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and transferred to 1.5 ml microfuge tube and centrifuged at 13,000-16,000 x g in a 
benchtop microfuge (Heraeus Instruments). Remove the supernatant, leaving 
behind 10 to 15 µl of residual liquid. After resuspending the cells by vortexing 
vigorously, 600 µl of Nuclei Lysis Solution was added to lyse the cells and 
pipetting until no visible cell clumps remain. A volume of 3 µl of RNase was 
added to the nuclear lysate and the sample mixed by inverting the tube 2 to 5 
times, and incubated at 37ºC for 15 to 30 minutes. After allowing the samples to 
cool down for 5 minutes at room temperature, 200 µl of Protein Precipitation 
Solution was added and the mixed using the vortex for 20 seconds and put on ice 
for 5 minutes. After centrifugation for 4 minutes at 13,000-16,000 x g, the 
precipitated protein was visible as a tight white pellet; the supernatant containing 
the DNA was removed and transferred to a clean 1.5 ml tube containing 600 µl of 
room temperature isopropanol. By gentle inversion, the solution was mixed until 
white thread-like strands of DNA was observable, and centrifuged using the 
microfuge for 1 minute, the DNA was then visible as a small white pellet and the 
supernatant carefully removed. At room temperature, the pellet was washed by 
adding 600 µl of 70% Ethanol. After centrifugation for 1 minute, the Ethanol was 
aspirated very carefully using either a Pasteur pipette or a pipette tip. The pellet 
was air-dried for 10 to 15 minutes, and the DNA rehydrated by adding 100 µl of 
DNA Rehydration Solution followed by an overnight incubation at room 
temperature or at 4ºC. 
The concentration of genomic DNA was quantified using Ultra-Violet 
spectrophotometer at a wavelength of 260 nm (A260). In addition, the purity of 
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the DNA extracted was calculated by using the ratio between the absorbance 
values at 260 and 280 nm.  
 
2.6. Extraction of RNA using TRIzol reagent 
 
TRIzol reagent is a ready-to-use reagent for the isolation of total RNA from cells 
and tissues. The reagent, a mono-phasic solution of phenol and guanidine 
isothiocyanate, is an improvement to the single-step RNA isolation method 
developed by Chomczynski and Sacchi in 1987. TRIzol reagent maintains the 
integrity of the RNA, while disrupting cells and dissolving cell components. 
After aspirating the media from the cells, the monolayer at 90 to 95 % confluent 
was washed twice with 10 ml PBS. The amount of TRIzol added is based on the 
area of culture dish, in our case 1ml of TRIzol reagent was added (usually 2 ml 
per ~2x10
6
 cells). The lysate was transferred to a 15 ml conical tube after 
retropipetting and stored at - 80°C. The above homogenisation step is followed by 
a phase separation, after incubation of the homogenised samples for 5 min at  
15-30°C to allow the complete dissociation of nucleoprotein complex, 200 µl of 
chloroform per ml of TRIzol was added and the tubes mixed vigorously by hand 
for 15 seconds and incubated at 15-30°C for 2-3 minutes. Then the samples were 
centrifuged at 13000 rpm for 30 minutes at 4°C. Following centrifugation, the 
mixture is separated into a lower red phenol/chloroform phase, an interphase and 
a colourless upper aqueous phase. The RNA remains exclusively in the upper 
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aqueous phase which is about 60 % of the volume of TRIzol reagent used for 
homogenisation. 
Once the aqueous phase was transferred to a fresh tube, the RNA was precipitated 
by gently mixing with 500 µl of isopropyl alcohol per ml of TRIzol reagent used 
for the initial step. The samples were incubated at 15-30°C for 10 minutes and 
then centrifuged at 13000 rpm (revolutions per minute) during 20 minutes at 4°C. 
After centrifugation, the RNA precipitate forms a gel-like pellet on the side and 
bottom of the tube. 
The supernatant is removed and the RNA pellet washed with 1 ml of 75 % 
Ethanol (1 ml of ethanol for 1 ml of TRIzol), the sample was mixed by vortexing 
followed by a centrifugation at 8000 rpm for 5 minutes at 4°C. The supernatant 
was decanted and the pellet air-dried at room temperature for 5-10 minutes, at the 
end of the procedure the RNA was dissolved by the addition of 20 µl of Diethyl 
PyroCarbonate (DEPC) treated water (Sigma-Aldrich, UK). The samples were 
incubated on ice for an hour or at 55-60°C for 10 minutes then stored at - 80°C. 
The concentration and quality of RNA were determined using a 
spectrophotometer by measuring the ratio between the absorbance values at 260 
and 280 nm. Pure preparations of RNA have A260/A280 ratio values in the range 
1.8 to 2.1. Preparation of 1 µg was visualised by electrophoresis in 1 % agarose 
gel stained with Ethidium Bromide and resulted in 2 bands that correspond to 18S 
and 28S ribosomal RNA sub units.  The total RNAs were then stored at - 80°C in 
1.5 ml microcentrifuge tubes for the next experiments.  
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2.7. Standard polymerase chain reaction (PCR) 
 
PCR is a reaction that allows the researchers to generate a large number of 
amplicons for a specific DNA sequence. A basic PCR set up requires several 
components and reagents usually in a final volume of 25 µl: a target DNA 
template to be amplified, two primers of approximately 20 bases which are 
complementary to the DNA regions at the 5‟end (forward primer) and 3‟ end 
(reverse primer), and a DNA polymerase enzyme like Taq polymerase. Also, 
dNTPs (Deoxynucleoside triphosphates) mix is necessary to synthesize the new 
DNA strand. All this reagents should be in an optimum reaction for the stability of 
the DNA polymerase which is a buffer solution containing magnesium and 
potassium.  
PCR consists of a series of 30 to 40 cycles of temperature changes, the 
temperatures used and the time applied in each cycle depend on a variety of 
parameters such as the melting temperature of the primers, concentration of 
dNTPs (Deoxynucleoside triphosphates). There are usually three different steps 
which can sometimes be preceded by a hot start step (>90°C) to activate the DNA 
polymerase if it is thermoactivated, between 1 to 10 minutes.  
The first PCR stage is the denaturation which consists of melting the double 
stranded DNA by disrupting the hydrogen bonds between the complementary 
bases and the temperature is usually between 94-98°C for 20-30 seconds. 
The next step is annealing, the temperature is lowered to 50-65°C for 20-40 
seconds in order to allow the primers to anneal to the DNA template and the 
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temperature is about 3-5 degrees Celsius below the Tm (melting temperature) of 
the primers used. Followed by elongation/extension step that is commonly at 72°C 
for around 30 seconds, the synthesis of the new DNA takes place during this step 
by adding complementary dNTPs. The last step of PCR is the final extension for 5 
to 10 minutes at 72°C to ensure that any remaining single-stranded DNA is fully 
extended.  
 
2.8. Agarose gel electrophoresis 
 
Agarose gel electrophoresis is a method to separate negatively charged DNA or 
RNA molecules according to size by applying an electric field through the gel, 
smaller molecules travel further on the agarose matrix which is a highly purified 
polysaccharide derived from agar. 
The preparation of 1% agarose gel consists of dissolving 1 g of agarose (Fisher 
Scientific, UK) in 100 ml of 1X TBE (Tris/Borate/ EDTA) (Fisher Scientific, UK) 
in a microwave for approximately 3 minutes until the homogenous mixture is 
transparent. After cooling the solution, 5 µl of ethidium bromide (10 mg/ml) 
(Fisher Scientific, UK) was added. Ethidium bromide (EtBr) is the most common 
dye used to detect DNA or RNA bands by fluorescence during exposure to UV 
light.  
After swirling the bottle gently, the gel was slowly poured into a castring tray 
containing sample combs to form the wells, and allowed to solidify at room 
temperature. After solidification, the combs were removed and the gel was 
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covered by few millimetres by TBE buffer. About 10-15 µl of each sample was 
loaded slowly into each well and about 5-8 µl of 1Kb plus ladder (Invitrogen, UK) 
was loaded into one well too in order to determine the size of the amplification 
products. Electrodes were connected to the apparatus and a constant current of 
about 60 to 70 volts was applied for half to one hour until the dye reached 
approximately ¾ across the gel. Finally, the gel was visualised under a UV 
illuminator and a picture taken by Alpha Imager 2200 (AlphaInnotech 
Corporation, USA).  
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CHAPTER 3 
 
 
MICROCELL MEDIATED CHROMOSOME TRANSFER TO 
IDENTIFY NOVEL MELANOMA TUMOUR SUPPRESSOR 
GENE ON CHROMOSOME 9p21 
 
 
3.1. Introduction 
 
Microcell Mediated chromosome Transfer (MMCT) is an approach originally 
developed in the 1970s as a consequence of somatic cell fusion studies between 
normal and malignant tumour cells (Harris et al., 1969). During that period, 
various techniques were developed for gene transfer such as chromosome-
mediated gene transfer (McBride and Ozer, 1973), microcell-mediated gene 
transfer (Fournier and Ruddle, 1977) and DNA-mediated gene transfer (Wigler et 
al., 1979). However, MMCT provides a practical way for the introduction of one 
single chromosome into recipient cells in order to identify loci associated with a 
variety of phenotypes including cancers, DNA repair genes, senescence-inducing 
genes and telomerase suppression genes (Meaburn et al., 2005) (Table 3.1). In 
fact, MMCT is a method of functional complementation whereby any measurable 
phenotype can be investigated. 
 
 
3 
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Phenotype Gene Identified Chromosomal 
Location 
References 
Tumour 
suppression 
p53 17p13.1 
Stanbridge 1992 
pRB 13q14.2 
KAI1 11p11.2 Dong et al., 1995 
CDKN2A 9p21 England et al., 1996 
THY1 11q23-24 Abeysinghe et al., 2003 
ADAMTS9 3p14.2 Lo et al., 2007 
Senescence 
To be identified 2q37 Uejima et al., 1998 
To be identified 4q33-q34 Bryce et al., 1999 
SEN16 16q24.3 Reddy et al., 1999 
DNA repair  
XRCC4 5q15-q12 Athwal and Kaur, 1996 
XRCC5 2q35 Hafezparast et al., 1993 
Telomerase 
suppression  
To be identified 3p14.2-p21.1 Tanaka et al., 1998 
To be identified 10p15.1 Nishimoto et al., 2001 
To be identified 3p12-21.1 Cuthbert et al., 1999 
Mismatch repair hMLH1 3p21 Koi et al., 1994 
 
Table 3.1: Examples of genes identified by MMCT. This technology played a key 
role in the identification of genes, loci or genomic regions that carry genes associated in 
different important cellular mechanisms. 
 
This approach has been a useful tool for the identification of chromosomes that 
carry tumour suppressor genes by the introduction of single human chromosomes 
into human cancer cell lines. The first successful transfer of single chromosome 
was reported by Fournier and Ruddle in 1977. Somatic cell hybrids were 
constructed by transferring murine chromosomes to mouse, Chinese hamster and 
human cells using MMCT and maintaining these chromosomes as functional 
elements within the host cell background. This methodology has been used by a 
number of research groups for various purposes such as the identification of genes 
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involved in diseases especially cancer. Chromosome transfer is a useful method 
for hunting tumour suppressor genes on chromosomes with high levels of loss of 
heterozygosity, for instance it has been successfully used for the identification of 
the functions of p53 and pRB as the most important tumour suppressor genes 
(Stanbridge, 1992).  
MMCT technique has been mainly used for tumour suppression studies. However, 
it has also been utilised to prove the presence or absence of specific genes that 
alter or reverse the phenotype of a cell in a detectable manner. As an example of 
this, transfer of chromosome 3 into a human colon tumour cell line HCT116 
mutated in the mismatch repair gene hMLH, restored normal levels of the 
mismatch repair activity (Koi et al., 1994).  
In addition to the discovery of tumour suppressors and mismatch repair genes, 
chromosome transfer was used to identify DNA repair genes, senescence-inducing 
genes and telomerase repressor genes (reviewed in Meaburn et al., 2005). Also,  it 
has been shown that heterospecific human:rodent microcell hybrids offer a better 
advantage compared to homospecific combinations (eg: human:human or 
rodent:rodent), because it is more straight forward to define the foreign 
chromosome using PCR analysis of sequence-tagged-sites (STS), genetic markers 
and chromosome painting (Newbold and Cuthbert, 1998). 
MMCT has also been valuable in creating animal models to analyse the functions 
of human genes in vivo, as shown by the study of Tomizuka and colleagues in 
1997, where human chromosomes or fragments of chromosomes were introduced 
into mouse embryonic stem cells (ES) generating transgenic mice.  
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Chimeric mice were created from the ES hybrids after injection into mice 
blastocysts and human genes were expressed in specific tissues such as 
immunoglobulin (Ig) that was detected in the sera of adult chimeric mice 
(Tomizuka et al., 1997).  
Construction of a highly stable panel of 23 hybrids representing all 22 human 
autosomes and the X chromosome was realised by Cuthbert and colleagues in 
1995 (at Brunel University, West London, UK). The library of hybrids was used 
in several genetic studies as a resource for the determination of gene functions, 
mapping and cloning. This panel consists of human:rodent monochromosomal 
hybrids, each hybrid contains a single intact human chromosome maintained in 
the rodent background by drug selection (Cuthbert et al., 1995). In order to 
construct these hybrids, the normal adult male dermal fibroblast cell strain 1BR.2 
was used as the source for the human chromosomes to be transferred and mouse 
A9 fibroblasts were used as recipient cells. Prior to this transfer, the introduced 
individual human chromosomes had to be tagged with a selectable marker. In 
doing so, the retroviral vectors tgLS(+)HyTK were used for transfection of the 
human cell line 1.BR2 by adding supernatants obtained from a packaging cell line 
(Lupton et al., 1991). The HyTk marker is a fusion gene that contains both 
enzymatic activities of hygromycin transferase (hph) gene and herpes simplex 
thymidine kinase (TK), this fusion gene permits positive selection (in) for the 
presence of the transferred chromosome by supplementing the culture media with 
hygromycin B antibiotic, and negative selection (out) by adding the toxic 
nucleoside analogue Ganciclovir to the media; in other words the marker provides 
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a facility to select for the absence as well as the presence of the human 
chromosome (Lupton et al., 1991; Newbold et al., 1995) (Figure 3.1). 
Exposure of the donor cells to colcemid during MMCT causes microdeletions of 
different sizes to transferred chromosomes, as a result of this, a subset of hybrids 
arising from monochromosome transfer experiment will fail to exhibit the studied 
phenotype such as tumour suppression. Thus, the segregant hybrids are very 
useful and provide a resource for mapping of novel genes using deletion analysis 
(England et al., 1996; Parris et al., 1999).  
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Donor cell line 
A9HyTK9a 
Mouse/human hybrid 
cells containing tagged 
human chromosomes 
      Cells are blocked in 
mitosis 
Exposure to 
colcemid for 48h 
Cytochalasin B and 
centrifugation 
Eventually, nuclear 
envelope forms around 
individual chromosomes 
Cell fusion with
PEG 
UACC-903 recipient cells 
Selection with 
Hygromycin B 
UACC-903 monochromosome 
hybrids containing HyTK-
tagged human chromosome 9 
Cell death  
Filtration of the 
microcell suspension 
Cytochalasin B causes 
blebbing of the membrane 
followed by enucleation by 
centrifugation 
Figure 3.1: A simplified diagram of the transfer of chromosome 9 into UACC-903 
recipient melanoma cell line using MMCT. 
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Previous study from Parris and colleagues in 1999, used two variants of 
chromosome 9 carrying microdeletions. Chromosome 9a contains small deletions 
in the locus INK4 for the CDKN2A and CDKN2B genes, and chromosome 9b 
harbours a larger deletion of approximately 3.07 Mbp between IFNA1 (telomeric) 
and the marker D9S171 (centromeric) (Figure 3.2). Suppression of 
tumourigenicity was observed in nude mice and no metastasis was seen after 
injection of suppressing hybrids constructed with the 9a transferred chromosome. 
In contrast, mice injected with hybrids constructed by the transfer of the 9b 
chromosome variant that harbours a larger deletion, displayed more rapid tumour 
growth than hybrids of 9a chromosomes. The difference between the two variants 
9a and 9b indicates the presence of TSG(s) at 9p21. 
 
In the present work, microcell mediated chromosome transfer was used where a 
variant 9a chromosome derived from a normal human fibroblast primary cell line 
(1BR.2) and maintained into a murine background (A9) was transferred into the 
highly tumourigenic malignant melanoma cell line (UACC-903).  
The transferred chromosome 9a harbours exon-specific microdeletions at the 
INK4 locus which contains the two genes CDKN2A and CDKN2B.  
 
 
 
 
 
Chapter 3: Microcell Mediated Chromosome Transfer             
 
       Page 64
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2:  Chromosomal region 9p21 and location of the deletions in 9a and 9b 
chromosomes transferred into the UACC-903 melanoma cell line. Differences 
between the two variants 9a and 9b indicates the presence of TSG between the 
markers D9S1846 and D9S171.  
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3.2. Method 
 
3.2.1. Microcell-Mediated Chromosome Transfer 
 
The donor cells used for MMCT were monochromosome hybrids containing the 
human chromosome 9 carrying a deletion at the INK4 locus, maintained in the 
murine background cells A9 by the selective antibiotic hygromycin B. The donor 
cell line will be referred to in the present work as A9HyTK9 cells. A9 mouse cells 
containing the human monochromosome were cultured in DMEM with 10% FCS, 
2 mM of L-Glutamine and 100 μg/ml of Penicillin and 100 μg/ml of 
Streptomycin. In addition 800 units of hygromycin B were added in the medium 
to maintain the human chromosome in the donor cells.  
MMCT method is performed as follows. On the first day, 1.5x10
6
 donor cells 
A9HyTK9 were seeded in 24 x 25cm
2
 flasks containing 20% FCS (10% already 
in the complete medium + 10% of the volume of FCS) in a volume of 5 ml per 
flask, without hygromycin B. The recipient cells UACC-903 were seeded at 1 x 
10
6
 in 10 cm tissue culture dish in a final volume of 15 ml complete medium. On 
the following day, a concentration of 0.075 μg/ml of colcemid was added to the 
donor cells and left to incubate for 48 hours. Exposure of cells to colcemid for 48 
hours results in the formation of micronuclei containing the genetic material of 
fragments of chromosome or sometimes a single chromosome (Newbold and 
Cuthbert, 1998) (Figure 3.3). 
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After 48 hours of incubation, the medium in the 24 flasks was aspirated and 
replaced by 30 ml of pre-warmed (37°C) serum free medium SFM supplemented 
with 10 μg/ml cytochalasin B (Sigma, UK) and incubated for 20 minutes at 37°C. 
Cytochalasin B makes the cell membrane more permeable which allows the 
microcells to be extruded to the cell surface which is confirmed visually by light 
microscopy. The flasks containing cytochalasin B with extruded microcells are 
weighed and paired by two (±0.02 g) to be centrifuged. To cushion the flasks 
during the centrifugation, 24 bottles of 75 ml of water are prepared the previous 
day and are stored at 37°C. The flasks were placed in the pots with the cell 
monolayer facing inwards and the lids pointing towards the rotor axis. The flasks 
were centrifuged for 1 hour and 15 minutes at 9500 x g in a Sigma manufacturer 
6k10 centrifuge. After centrifugation, the supernatant containing cytochalasin B 
was aspirated leaving about 2ml, was transferred into a 1 litre bottle, filtered and 
stored at 4°C for use in the next MMCT experiment. 
The flasks were flicked and the microcells resuspended by thorough pipetting. 
The microcells were then collected in 4 tubes of 15 ml and centrifuged for 5 
minutes at 4500 rpm in Heraeus megafuge 1.0.  The medium was aspirated and 
the pellet resuspended in 1.5 ml of SFM for approximately 2 to 3 minutes to 
create a suspension of microcell. Serum free medium was added in the tubes up to 
12 ml, each tube was then filtered and purified once through 8 μm sterile 25 mm 
nucleopore polycarbonate filters and twice through 5 μm filters (Labscale 
Company, Over Industrial Park, Cambridge, UK), held in swinlock filter holders 
(Labscale) and followed by a centrifugation at 4500 rpm for 5 min. The 
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supernatants were aspirated off, and the pellets resuspended in 3 ml of 
Phytohaematogglutinin PHA-P (150 μl of 100 μg/ml of PHA-P + 3 ml of SFM).  
Meanwhile, the UACC-903 recipient cells were washed three times with 10 ml 
SFM for each wash. The 3 ml of PHA-P containing the microcells were 
transferred to recipient cells and were incubated at 37°C and 10% CO2 during 25 
minutes (PHA-P agglutinates the microcells to the recipient cells). Another 3 ml 
of PHA-P only is added to a UACC-903 plate for control. 
After the incubation of 25 to 30 minutes, the microcells were aspirated off and 
3ml of Polyethylene Glycol (PEG) solution containing 42.5% of PEG and 8.5% 
DMSO in SFM was slowly added to the edge of the plate, then covering all the 
monolayer. The timer was set at 1 minute but the PEG was aspirated after 50 
seconds, this is important in order to avoid fusion of whole cells. The same was 
done for the control plate. 
The plates were washed with 10ml of prewarmed SFM three times, the plates 
were gently swirled and the medium aspirated after 40, 50 and 60 seconds 
respectively.  Then 15 ml of complete medium (DMEM + 10% FCS) was added 
and the plates were incubated at 37 C and 10% CO2. The same steps were 
followed for the control plate. 
The next day, each plate was subcultured in ten dishes in 15 ml of complete 
medium. After 48 hours, the medium was aspirated from the 10 dishes and 15 ml 
of medium was added containing 300 units/ml of hygromycin B and was replaced 
every week by fresh medium containing the same concentration of hygromycin B.  
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(a)                                                          (b) 
                                                     
(c)                                                            (d) 
 
Figure 3.3:  Images showing the different steps of MMCT. 
(a) The human: rodent A9 somatic donor cells containing a single human 
chromosome 9a tagged with the hygromycin gene. (b) Donor cells A9a treated for 
48 hours with colcemid causing micronucleation. (c) Exposure of micronucleated 
cells to cytochalasin B. (d) Micronucleated cells after 25 minutes exposure to 
cytochalasin B showing blebbing of the membrane. Scale Bar: 40 μM.  
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3.2.2. Isolating UACC-903 hybrids containing a transferred chromosome 9a  
 
After 3 to 4 weeks, hygromycin B resistant colonies were detected by 
visualisation using phase contrast microscopy. The colonies were chosen and 
marked by drawing a circle under the dish. The medium was aspirated and cells 
washed with versene. The colonies were harvested using cloning rings placed on 
top of the marked colony with grease (Vaseline) on the edge allowing the cloning 
ring to make a tight seal. The cylinder was pressed slowly with forceps and 
trypsine was added inside with a fine bore pipette then was aspirated when the 
cells were detached; and transferred to a T25 flask containing 150 units/ml of 
hygromycin B. The cells were then maintained in culture and expanded. 
 
3.3. Results 
 
Hybrid cell lines have been generated by the transfer of single chromosome 9a 
present in murine:human hybrid cell lines. The tagged chromosomes have been 
maintained into the A9 recipient cells by adding 400 units/ml of hygromycin B in 
the culture media. After harvesting the clones, the different hybrids were 
expanded by subculturing them and stored in liquid nitrogen.  
In the present study, hybrids were constructed after isolation of the clones (Table 
3.2). The number of clones was different from one chromosome transfer to the 
other.  
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Transfer of chromosome 9  
MMCT Donor cells  Recipient cells  Number of hybrids 
1 A9HyTK9a p 3  UACC-903 p 85 0 
2 A9HyTK9a p 3 UACC-903 p 78 5 
3 A9HyTK9a p 10 UACC-903 p 79 0 
4 A9HyTK9a p 9 UACC-903 p 84 9 
5 A9HyTK9a p 9 UACC-903 p 84 2 
6 A9HyTK9a p 9 UACC-903 p 85 12 
  
  Table 3.2: Microcell-mediated chromosome transfer of chromosome 9a into UACC-
903 melanoma cell line.  
 
3.4. Discussion 
 
A number of hybrids have been constructed via microcell mediated chromosome 
transfer technique by the introduction into UACC-903 melanoma cell lines of a 
derivative of chromosome 9 carrying a deletion at the INK4 locus tagged with 
HyTK dominant marker which is a fusion gene that contains both enzymatic 
activities of hygromycin transferase (hph) gene and herpes simplex thymidine 
kinase (TK) thus conferring resistant to the antibiotic hygromycin B.  
The transfer of a single intact copy of any chromosome into the UACC-903 cell 
line used in this study did not affect their growth in culture (Parris et al., 1999).  
However, 24 hours after the transfer, the UACC-903 confluent monolayer was 
split into 10 Petri dishes in media with hygomycin B and most of the cells were 
dead after 24-48 hours of selection. After approximately one week to ten days, 
clusters of cells were observed indicating the formation of colonies.  
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However, MMCT is a technique that has variability in occurrence. Table 3.1 
shows this variability, the efficiency for the production of hybrids depends upon 
the sensitivity of the chromosome transfer. In fact, one of the important factors to 
a successful chromosome transfer is the recipient cells. The recipient UACC-903 
cells had to be at 95% confluency and there should be no space during the cells in 
order to increase the chances of the microcells to fuse with UACC-903 cells. 
 
Several methods have been developed for testing tumourigenicity. One of the 
main procedures used to assess the potential of cell lines to form tumours, is the 
development of tumour models by injection of the cells subcutaneously in nude 
athymic (nu/nu) mice (T-cell deficient) or SCID (Severe Combined 
Immunodeficiency) mice. The SCID mouse show an immunodeficiency that 
affect both T and B lymphocytes (Bosma et al., 1983) which makes it an ideal 
animal model for tumourigenicity studies because it allows growth of human 
tumours over a short period of time. Also, human xenografts tumours method 
(cross-species transplantations) allowed efficient proliferation of human tumour 
tissues in strain nude or SCID mice without rejection of the transplants (Morton 
and Houghton, 2007). However, these in vivo methods for assessing 
tumourigenicity have some disadvantages such as the costs for breeding and 
maintaining that could not be afforded during the PhD.  
Clonogenic assays are a good indicator for tumourigenicity and have been used as 
a major application for testing tumours and xenografts. The method is commonly 
used in oncological research to evaluate the proliferative capacity of cancer cells 
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(Hamburger and Salmon, 1977). Fiebig and his colleagues (2004) have compared 
the response of human tumours established as xenografts in nude mice and tumour 
clonogenic assay in a study for drug sensitivity and resistance. Their findings 
show that the results obtained by the in vitro assay and the clinical response to the 
drug were about 90%. Therefore, tumour clonogenic assays have an important 
role in oncological research such as testing anticancer drugs. 
The ability to proliferate in semi-solid medium, a property described as 
anchorage-independent growth, is demonstrated by the soft agar assay which was  
the in vitro technique used in the present study in order to evaluate 
tumourigenicity which is also widespread for mapping for novel genes. The 
constructed hybrids were tested for their ability to form colonies of soft agar as 
explained in chapter 4. 
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CHAPTER 4 
 
 
TUMOURIGENICITY OF UACC-903/9a HYBRIDS 
MEASURED BY ANCHORAGE INDEPENDENT 
GROWTH IN A SOFT AGAR ASSAY 
 
 
4.1. Introduction 
 
Most of the cells of the body have to be physically attached to the extracellular 
matrix in order to grow and differentiate normally. Anchorage dependent growth 
is a characteristic of most type of cells with the exception of blood cells. The 
attachment of the cell to a solid surface is required for the control of cell division 
(Assoian, 1997). Many transformed cells are characterised by the loss of 
anchorage dependent growth, and the close relationship between anchorage 
independent growth and tumourigenicity has been demonstrated by several 
studies. 
Many tumour cells are characterised by phenotypic and molecular changes, these 
features correlate with oncogenic transformation of the cells. A summary of some 
of the properties acquired by transformed cells is shown in Table 4.1 (Hall, 2002). 
 
 
4 
Chapter 4: Soft Agar Assay   
       Page 74
   
 
 
Phenotypic and molecular features of 
tumour cells 
Description 
 
 
Loss of contact inhibition 
Normal cells stop dividing when they touch 
each other as a consequence of signals 
between neighbour cells. Tumour cells 
continue dividing because of interruption of 
the signals to stop division. 
Anchorage independent growth Normal cells (eg. Fibroblasts) grow only if 
they are attached to solid substrate. In 
contrast, tumour cells lose this feature. 
Immortality Unlimited number of cell division. 
Molecular alterations in key regulatory 
genes 
Mutations that can activate oncogenes and 
inactivate tumour suppressor genes. 
Altered surface properties Changes in surface carbohydrates and 
antigens and charge.  
Increased motility Develop invasive properties 
Reduced requirements for serum (in 
vitro) 
Tumour cells can grow and developed even 
without additional growth factors in the 
medium. 
 
Table 4.1: Some of the properties characterising tumour cells (Hall, 2002).  
 
Anchorage independent growth is a hallmark of cell‟s transformation, the cells 
become able to divide and grow with the absence of adhesion to the extracellular 
matrix. This feature can be introduced by the modification of the signalling 
pathways, changes in growth factors, changes in the cytoskeleton but the exact 
mechanisms underlying loss of anchorage dependent growth are being 
investigated by various research groups. 
It is known that normal cells require signalling functions between growth factors 
and growth factor receptors and also interactions between cell surface molecules 
and the extra cellular matrix for growth and survival (Assoian, 1997). In response 
to anchorage deprivation, normal cells undergo programmed death by triggering 
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apoptosis mechanisms also called anoikis (Assoian, 1997; Frisch and Screaton, 
2001). There has been evidence suggesting that the ability of transformed and 
cancer cells to have reduced requirements for adhesion to the substratum was due 
to the inhibition of apoptotic-related pathways (Grossmann, 2002). Furthermore, 
integrins are cell surface receptors that interact with the ECM. They play a major 
role in the attachment between the cells and the surface; also integrins mediate 
several intracellular signalling pathways (Buck and Horwitz, 1987). It has been 
demonstrated that disruptions of some signalling pathways was due to the loss of 
cell adhesion mediated by integrins. Over-expression of the integrin-linked kinase 
promotes anchorage independent cell cycle progression, resulting in the 
stimulation of G1/S cyclin-CDK activities (Radeva et al., 1997).  
The transforming growth factor β (TGFβ) induces anchorage independent growth. 
This phenotypic transformation induced by TGFβ has been observed in few cell 
lines only such as NRK fibroblasts (Guadagno et al., 1993). However, this 
induction is rarely observed because TGFβ is considered as a proliferation 
inhibitor but a study conducted by Zhu et al., in 2000, showed that induction of 
anchorage independent growth needs other factor to activate this transformation 
through TGFβ such as the expression of cyclin D1.  
Cytoskeletal alterations are frequently observed in tumour cells, and changes of 
the cytoskeleton are very important for the anchorage independent growth of 
transformed cells (Pawlak and Helfman, 2002). Actin microfilament organisation 
is disrupted because of the reduction of the actin binding protein tropomyosin I, 
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this observation is believed to be due to the down-regulation of the topomyosin I 
synthesis (Boyd et al., 1995). 
Benecke and colleagues showed in 1978 that the incubation of cells in the absence 
of solid surface or anchorage, results in a reduction of 5 fold in mRNA production 
within a few hours, and consequently a reduction in protein synthesis. However, 
this type of responses to the loss of anchorage dependence by putting the cells in 
suspension are reduced or modified as the cells become progressively transformed 
in behaviour (Wittelsberger et al., 1981).  
A study conducted in 1975 by Shin and co-workers, showed that rodent cells 
displaying anchorage-independent growth were able to form tumours in nude 
mice. Mouse 3T3 cells and primary rat embryo cells infected by simian virus 
(SV40) have been tested for tumourigenicity into the deficient nude mice. As a 
result, the injected cells displayed an ability to proliferate in vitro in the absence 
of anchorage.  
One convenient assay of the anchorage-independent growth is the colony forming 
ability on a semisolid agar medium. In addition, the assessment of oncogenic 
capability of cells in soft agar has been proven to be a reliable technique for the 
study of the properties of tumour cells. The anchorage independent growth was 
first developed in human cells by Hamburger and Salmon in 1977. The authors 
developed an in vitro assay that allowed the formation of colonies of human 
myeloma stem cells in soft agar. They took adherent spleen cells from BALB/c 
mice previously injected with 0.2 ml mineral oil 4 weeks, to prepare conditioned 
medium for the assay. Then, 5 x 10
5 
cells derived from bone marrow of myeloma 
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patients were suspended in 0.3% agar in growth medium and plated. Final counts 
of the colonies were made 2 to 3 weeks after plating and the counted colonies 
consisted of 40 to hundreds cells with a diameter >2 µm. The number of colonies 
counted from bone marrow cells from the patients were 80 to 150 colonies. The 
bone marrow cells from normal volunteers developed 1 to 4 colonies per 5 x 10
5
. 
This assay indicated a difference between tumourigenic and non tumourigenic cell 
populations and demonstrated that tumourigenic cells display anchorage-
independent growth.  
Soft agar assay is a reliable technique for tumourigenicity by measuring the ability 
of the cells to proliferate in a semi-solid medium. It has been used for the 
screening of hybrids resulting from the fusion of normal human fibroblasts and 
carcinogen-transformed baby hamster kidney (BHK) immortalised cell line, the 
hamster cell line displayed an anchorage independent growth (Stoler and Bouck, 
1984). However, the anchorage independent growth phenotype was suppressed by 
only hybrids that retain chromosome 1, thus providing an evidence of the 
presence of growth suppressing genes located in chromosome 1.  
Also, in vivo studies have confirmed the correlation between anchorage 
independent growth and tumourigenicity. Lugo and Witte (1988) demonstrated 
that the expression of the oncogene tyrosine kinase P210, the product of the BCL-
ABL fusion gene in Rat-1 cells resulted in lost of the cell contact inhibition and a 
transformed phenotype and morphological change. Furthermore, subcutaneous 
inoculation of P210 expressing Rat-1 cells into nude mice resulted in tumour 
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formation after 12 weeks. On the other hand, inoculation of parental Rat-1 cells 
developed slow growing tumours.    
It has been demonstrated that there are phenotypic differences between cells 
derived from different stages of melanoma, when grown in tissue culture or 
injected in animals (Herlyn et al., 1985). Only metastatic and VGP melanoma 
cells formed tumours in nude mice, and show non random chromosomal 
abnormalities involving chromosomes 1, 6 and 7.  
The colony-forming efficiency in soft agar is an in vitro indicator of 
tumourigenesis making it an ideal assay to use in the present study where the 
constructed hybrids were assessed for colony formation ability.  
The tumourigenic human melanoma cell line UACC-903 has been used in several 
studies for the understanding of the mechanisms underlying cutaneous malignant 
melanoma (Robertson et al., 1996a; Su et al., 1996). Therefore, the use of UACC-
903 as the recipient cell line during chromosome transfer and the soft agar assays 
in this study was an ideal choice for this study. 
 
4.2. Method 
 
These assays were conducted in order to demonstrate the anchorage-independent 
growth which is described as the ability to proliferate in a semi solid medium, a 
characteristic of tumour cells. In the present study, soft agar assays have been 
used to identify the hybrid cells UACC-903 containing the human chromosome 9, 
and to display suppression of anchorage-independent growth.  
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The method consists in the preparation of the stock solutions for both the top and 
the base layers. The bottom layer containing 6% was prepared by making up 6 gm 
of Agar Noble with 10 gm Bacto Peptone and bringing the volume with ddH2O to 
a total of 100 ml. For the base layer, in a total volume of 100 ml ddH2O, 3.3 gm of 
Agar Noble was mixed with 10 gm of Bacto Peptone and a 3.3% agar solution 
was obtained. The agar solutions were sterilised by autoclave or pressure cooker 
and aliquots of 10-20 ml were prepared before the agar sets hard.                          
On the day of the experiment, the appropriate amount of both 6% and 3.3% soft 
agar was solubilised by boiling. The agar was then placed in the water bath set at 
55-60°C to keep the agar molten. The base layers were set by pouring 4 ml of soft 
agar solution in the appropriate number of 6 well plates (Nunclon, UK) and was 
left to set. For instance, the dilution of the 6% soft agar mixture can consist of 
mixing 90 ml of complete growth medium with 10 ml of molten agar 6%. The 
cells were trypsinised and counted to derive a final appropriate concentration 
required for each plate. Then, 1.6 ml of molten 3.3% agar was mixed with 13.4 ml 
of medium and 1 ml of cells (1 x 10
4 
cells) was added and also the appropriate 
volume of 300 units/ml of hygromycin B (about 11-12 μl), giving a final volume 
of 16 ml of top layer that was distributed by pouring 4 ml in each well, each 
hybrid was screened in triplicate.  The plates were placed in the incubator at 37°C 
and 10% CO2. After 3 to 4 weeks, the colonies were counted. 
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4.3. Results 
 
Cells possessing a tumourigenic phenotype and anchorage independent growth 
can be assessed by the ability to proliferate on a semi-solid medium. The 
hygromycin resistant hybrids constructed using MMCT have been taken through 
soft agar assay to analyse whether the transfer of single chromosome 9 deleted for 
the INK4 locus can suppress tumourigenesis. Colonies of different sizes were 
visualised using an inverted light microscope (Olympus, UK), small colonies were 
formed by less than 50 cells and were not counted. However, colonies formed by 
more than 50 cells were counted and the colony forming efficiency (CFE) was 
calculated by dividing the number of colonies by the number of cells seeded and 
expressed as a percentage.   The monochromosome hybrids that display colony 
formation efficiencies of less than 1% were regarded as suppressed. In this hybrid 
set, it was observed that the majority of colonies were small in size and comprised 
less than 50 cells. This is in contrast to parental UACC-903 and non-suppressed 
hybrids where colonies were microscopically visible and composed of many 
thousands of cells. The results obtained for this study are summarised in Figure 
4.1, and the values are the means based on two soft agar assays. The parental 
melanoma cell line was used as a control in soft agar and produced colony 
forming efficiency of 21 %.   
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Figure 4.2: Average colony forming efficiency (CFE) of the constructed hybrids 
UACC-903/A9HyTK9a. 22 hybrids with hybrids in red showing segregation (NS = non-
suppressor) and hybrids in blue demonstrating growth suppression with CFE < 1% 
(S=suppressor). Errors bars represent standard error of the mean which were no greater 
than 4.03% (NS2 standard error).   
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4.4. Discussion  
 
Soft agar assay of the hybrids generated by the transfer of chromosome 9 
harbouring a small deletion in the INK4 locus (deletion of p16 and p15) into the 
highly tumourigenic human melanoma cell line UACC-903 resulted in the 
characterisation of two categories of hybrids. Hybrids demonstrating growth 
suppression in soft agar (suppressors) and others did not exhibit growth 
suppression (non suppressor hybrids).  
Chromosome 9 has been implicated in the etiology of cutaneous melanoma and 
p16 has been demonstrated by various studies to be the most well characterised 
gene involved in development of melanoma. However, a study conducted by 
England and colleagues in 1996 showed that the transfer of an intact chromosome 
9 into human malignant melanoma cell lines deficient for p16 induces growth 
arrest in the cultures. Hence, growth suppression conferred by the transfer of 
chromosome 9 is very interesting as it implies that another growth suppressor 
locus is present on 9p21 that functions independently of p16 gene. This 
observation was further confirmed by Parris and colleagues in 1999 where tumour 
suppression was observed after the introduction of chromosome 9 derivatives (9a 
and 9b variants) into the UACC-903 melanoma cell line, the results observed 
were significant as the introduced chromosomes conferred growth suppression in 
soft agar in the absence of p16 which was inactivated or deleted in the 
chromosome 9 variants as well as in the parental melanoma cell line, further 
implying that another growth suppressor locus is present on 9p21 that functions 
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independently of p16. Pollock and colleagues also confirmed the presence of at 
least three tumour suppressor loci in the chromosomal region 9p21 involved in the 
development and progression of cutaneous malignant melanoma (Pollock et al., 
2001).  
In addition, the construction of segregant hybrids that demonstrate the reverse 
phenotype of anchorage independent growth because of micro deletions in regions 
that may carry a tumour suppressor gene locus in the transferred chromosomes, 
are an invaluable resource for identifying regions that contain the genes which 
confer growth suppression in soft agar.  
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CHAPTER 5 
 
GENE EXPRESSION ANALYSIS OF GENES IN 
CHROMOSOMAL REGION 9p21 
CHAP 
TER 
 5: CASE STUDIES AND RESEARCH 5.okmokmokm 
5.1. Introduction 
 
 
The discovery of all tumour suppressor genes implicated in human cancer is a 
central goal of the study of cancer genetics. The genomic location and function of 
these genes will likely provide novel therapeutic targets for the treatment of 
cancer in the future. Tumour suppressor genes act as negative regulators of cell 
division. This control is lost when tumour suppressor genes are inactivated which 
can cause the development of a malignancy.  
This study aims to characterise potential tumour suppressor genes located in the 
chromosomal region 9p21 which may be involved in the development of CMM. 
There is a strong evidence for the presence of a tumour suppressor gene(s) 
functioning independently of p16 residing between IFNA and MTAP genes and 
the availability of two variants of chromosome 9 (9a and 9b) as described in the 
previous chapter harbouring different microdeletions provides an opportunity to 
identify the tumour suppressor gene(s). In addition, mice injected with hybrids 
constructed by the transfer of the 9b chromosome variant which harbours a larger 
 
5 
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deletion compared to chromosome 9a, displayed more rapid tumour growth than 
hybrids of 9a chromosomes which exhibited prolonged tumour suppression 
(Parris et al., 1999).  
The introduction of a variant of chromosome 9 deleted for the INK4 locus only 
(A9HyTK9a) into the highly tumourigenic melanoma cell line UACC-903 by 
microcell mediated chromosome transfer resulted in the construction of thirty 
hybrids. They were then tested for tumourigenicity by evaluating the ability to 
form colonies using soft agar assays (anchorage independent growth). A 
proportion of the constructed hybrids exhibited segregation (did not exhibit 
suppression of anchorage independent growth) whilst other hybrids demonstrated 
suppression of tumourigenicity. The generation of suppressor and segregant 
hybrids, due to microdeletions occurring during the transfer, is a valuable resource 
for the characterisation of the regions that are deleted in the segregant hybrids. 
The association of a deletion and the lack of tumour suppression potentially 
identifies the location of novel tumour suppressor loci.  
The following chapter describes and analyses the approach undertaken in order to 
conduct a gene expression analysis of all the genes present in the region of 
chromosome 9p21 between markers IFNA and MTAP. Differences in gene 
expression patterns between the suppressor and segregant hybrids might be 
associated with the presence or absence of tumour suppressor genes. In doing so, 
several methods have been taken into consideration for gene expression analysis. 
Microsatellite analysis can be used to define regions of loss of heterozygosity, for 
instance the tumour suppressor gene TUSC1 located in the region 9p21 has been 
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identified using STS (sequence tagged site) mapping and homozygously deleted 
regions were detected by reverse transcription PCR (Shan et al., 2004). However, 
this method could not be applied for this study because it is usually used for 
genotyping for identification of deleted loci. In addition, the aim of the gene 
expression analysis was to specifically check for expression for each gene located 
at chromosome 9p21 rather than detecting regions of homozygous deletion. 
Another approach used for gene expression profiling is microarray technology 
which is considered as a valuable strategy for identifying novel disease-related 
genes and to understand the initiation and progression of cancer and other 
diseases. 
DeRisi and colleagues in 1996 were one of the first groups to use high throughput 
DNA microarray technology to examine gene expression in melanoma. They used 
a chip of around 1100 genes associated with tumour progression in the human 
melanoma cell line UACC-903. This approach had lead to the identification of 
several candidate genes and melanoma-antigens that play a role in melanoma 
progression.  
Recent advances in bioinformatics and high-throughput technologies such as 
microarrays have been widely used in identifying molecular mechanisms 
underlying normal and dysfunctional functions. Microarray is a technology 
consisting of an array of samples representing thousands of DNA nucleotides that 
can be analysed for expression in a highly efficient manner. Gene expression 
profiling using microarray technology has been useful to assess gene expression 
levels of RNA. 
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Hence, complementary DNA microarray technology has been used to study gene 
expression patterns in cutaneous malignant melanoma (Carr et al., 2003). 
It has been shown that most studies utilising high-throughput gene expression 
analysis have had a major impact in melanoma research and the development of 
gene expression platforms provided important data for the future development of 
melanoma prognostic markers and therapies (Ren et al., 2008). Despite the fact 
that microarray technology had helped in the identification of several genes 
involved in melanoma, this approach was not chosen for the current study because 
the gene expression analysis was carried out for 23 genes only. Also, the cost 
required for the microarray chip and reagents was relatively high for the analysis 
of the expression of 23 genes.  
 
Northern blot is a standard method for detection and quantification of RNA levels 
but has some limitations such as the sensitivity compared to reverse transcription 
PCR. 
Reverse transcriptase polymerase chain reaction (RT-PCR) is a very powerful and 
sensitive technique to measure and compare gene expression at the mRNA level 
among samples by reverse transcribing RNA into cDNA (complementary DNA).  
RT-PCR method was used for the present study in order to investigate the 
expression of the genes located in the chromosomal region 9p21. More precisely, 
the investigation was based on the expression of the genes only in suppressed cell 
lines but not in non suppressed constructed hybrids.  
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5.2. Materials and Methods 
 
5.2.1. Candidate genes in the region of chromosome 9p21 
 
It was possible to obtain an updated map of the position of the genes in the region 
9p21 using the NCBI database (National Center for Biotechnology Information), 
more specifically by accessing Map Viewer which is available on the database 
(http://www.ncbi.nlm.nih.gov/mapview/).  
Map Viewer provides a wide variety of genome mapping and sequencing data 
from different organisms. The map was constructed by accessing the current 
Homo sapiens (Human) genome build 36.3 that offers an up-to-date gene position. 
However, it was important to check the location of the genes as the database is 
often updated and genes location is modified. New entries are added and even 
some genes discontinued.  
Based on the NCBI search, some of the genes in the 9p21 region were 
pseudogenes. Pseudogenes are non-functional copies of genes that lost their 
protein-coding ability (Vanin, 1985). Most of the pseudogenes can not be 
expressed because they lack the ability to encode RNA or proteins because of 
various genetic disruptions such as stop codons, frameshifts, or lack of 
transcription (Harrison et al., 2003). However, pseudogenes are important 
resource for comparative genomics because of their evolutionary conservation of 
gene sequences.   
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In the present study, 17 pseudogenes were present in the region 9p21 (Figure 3.2) 
and were not included in the gene expression analysis because they do not code 
for a protein and they can complicate molecular genetic studies because PCR 
amplification of these genes can result in amplification of genes that have similar 
sequences.  
Below is the list of the 23 functional genes present in the region of 3.5 Mb at the 
chromosomal region 9p21 that have been analysed for expression using RT-PCR 
(Table 5.1). 
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Genes on chromosome 9p21 
Gene Name Description/ Function 
IFNB1 Interferon Beta 1 Induces transcription of the p53 gene and increase p53 protein levels (Takaoka et al., 2003) 
IFNW1 Interferon Omega 1 Member of type I interferons family 
IFNA21 Interferon Alpha 21 Positioned in the cluster of IFN-α genes  by deletion mapping (Olopade et al., 1992) 
IFNA4 Interferon Alpha 4 Positioned in the cluster of IFN-α genes  by deletion mapping (Olopade et al., 1992) 
IFNA7 Interferon Alpha 7 Positioned in the cluster of IFN-α genes  by deletion mapping (Olopade et al., 1992) 
IFNA10 Interferon Alpha 10 Positioned in the cluster of IFN-α genes  by deletion mapping (Olopade et al., 1992) 
IFNA16 Interferon Alpha 16 Positioned in the cluster of IFN-α genes  by deletion mapping (Olopade et al., 1992) 
IFNA17 Interferon Alpha 17 ile184arg (I184R): role in risk and prognosis of cervical cancer (Kim et al., 2003) 
IFNA14 Interferon Alpha 14 Positioned in the cluster of IFN-α genes  by deletion mapping (Olopade et al., 1992) 
IFNA5 Interferon Alpha 5 Positioned in the cluster of IFN-α genes  by deletion mapping (Olopade et al., 1992) 
KLHL9 Kelch-like 9 (Drosophila) Interacts with 370KDa protein complex in HeLa cell lysates (Sumara et al., 2007) 
IFNA6 Interferon Alpha 6 Positioned in the cluster of IFN-α genes  by deletion mapping (Olopade et al., 1992) 
IFNA13 Interferon Alpha 13 Positioned in the cluster of IFN-α genes  by deletion mapping (Olopade et al., 1992) 
IFNA2 Interferon Alpha 2 Used for adjuvant therapy to treat high-risk cutaneous melanomas (Dithmar et al., 2000) 
IFNA8 Interferon Alpha 8 Positioned in the cluster of IFN-α genes  by deletion mapping (Olopade et al., 1992) 
IFNA1 Interferon Alpha 1 
Induces transcription of the p53 gene and increase p53 protein levels (Takaoka et al., 
2003). Used in adjuvant therapy of melanoma.  
IFNE1 Interferon Epsilon 1 
Unknown function but the structure and mRNA expression pattern  suggest that it may 
have a function distinct from those other members of type I INF (Hardy et al., 2004) 
MTAP 
methylthioadenosine 
phosphorylase 
Major role in polyamine metabolism, and is important for the salvage of both adenine and 
methionine. Complete or partial deletion in some malignant cell lines (Nobori et al., 1996)   
CDKN2A 
cyclin-dependent kinase 
inhibitor 2A 
Encodes for p16 an inhibitor of CDK4 kinase and an important tumour suppressor gene 
frequently mutated or deleted in a wide variety of tumours.  
Encodes for p14 ARF functions as a stabilizer of the tumour suppressor protein p53 as it 
can interact with, and sequester, MDM1, a protein responsible for the degradation of p53 
CDKN2B 
cyclin-dependent kinase 
inhibitor 2B 
Encodes for p15 a cyclin-dependent kinase inhibitor, which forms a complex with CDK4 or 
CDK6  
DMRTA1 DMRT-like family A1 Unknown function. 
ELAVL2 
embryonic lethal 
(Drosophila) 
Homolog to human Hel-N1, expressed in neurons. Absence causes multiple structural 
defects in the central nervous system (King et al., 1994). 
TUSC1 
tumor suppressor 
candidate 1 
Deleted in nonsmall cell lung carcinomas (NSCLC) and SCLC cell lines, potential lung 
cancer tumour suppressor genes in a region of LOH on 9p (Shan et al., 2004). 
 
Table 5.1: List of the functional genes present in the chromosomal region 9p21 with 
description and protein function.  
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5.2.2. Primer design 
 
Primer sequences were designed prior to RT-PCR. A primer is a short segment of 
DNA that is complementary to the desired target genomic DNA or cDNA 
sequence to be amplified. Also, primers are selected to specifically match a cDNA 
and no other sequence in the genome. A set of primer sequences that matches 
different DNA targets results in non-specific amplification.  
Several rules are followed when designing primers because the length and the 
sequence are critical parameters of a successful amplification. The primers consist 
in a set of two short sequences: forward primer (5‟ to 3‟ sense) and reverse primer 
(reversed and complemented 3‟ to 5‟ anti-sense). In general, primer‟s length 
should be between 20 and 25 bp (base pair) with a GC percentage of 50 to 60.  
Another important parameter is the melting temperature (Tm) which is the 
temperature at which 50% of the double stranded DNA will dissociate to become 
single stranded. The annealing temperature (Ta) is usually around 5°C below the 
Tm. Also, the 3‟ ends of the primers should not be complementary in order to 
avoid the synthesis of primer dimers during amplification.  
 
Different methods have been used in order to design primers for the target genes 
to be amplified. The primers for the interferon β 1 (IFNB1) gene have been 
selected from a published paper by Zhang et al., 1996 as well as the PCR 
conditions and the product size.  
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Some tools that design primers are available online such as Primer 3 (v. 0.4.0) 
(Rozen and Skaletsky, 2000). Primer 3 has been used to design a set of primers 
specifically for the interferon α 1 gene (IFNA1) only. The IFNA1 and IFNA13 
genes have 73.7% similarity when the transcript sequences were compared using 
Pairwise Alignment Algorithms from EMBL-EBI database (Labarga et al., 2007). 
Thus, the forward and reverse primers have been designed from the 5‟ end of the 
IFNA1 where there are no similarities to any other gene. 
Other genes have been analysed for expression using UniSTS polymorphic 
markers from the NCBI website.  
A tool has been used for designing the primers of the other 22 genes in the region 
9p21 called Primer Express Software v2.0 from Applied Biosystems (California, 
USA). Primer Express is a software that designs primers and probes for PCR, the  
sequence of the gene is entered in the query box and a list of available primer sets 
is provides with primer sets specifications such as CG%, Tm (Figure 5.1).  
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Figure 5.1:  Output of list of primers for the gene IFNA1 using Primer Express, 
the software provides information about each primer and the products.  
 
 
The selected primer sets (Table 5.2) were analysed using one of the available 
online softwares The Basic Local Alignment Search Tool (BLAST) that finds the 
regions in the genome that match the primers. BLAST is accessible through NCBI 
database and it is a program that uses algorithms to compare the nucleotide or 
protein query to the databases.  
The importance of using BLAST was to determine whether the selected primer 
sequence matches the target sequence of interest only, or if it aligns with different 
transcripts or genomic human sequences. The best primers were the ones that had 
a single alignment of 100% corresponding to the target gene.  
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In addition, it is possible to blast both forward and reverse primers at the same 
time using the new tool NCBI primer-BLAST in order to retrieve the primer pairs 
that can cause amplification of targets other than the input template or the single 
target sequence to be amplified. Below is an example of the use of primer-BLAST 
showing that the primers set for the gene IFNB1 matches only IFNB (Figure 5.2). 
 
 
Figure 5.2: Primer-BLAST results for IFNB1 primers. The primers pair matched 
one single product which is the IFNB1 transcript showing also the primers 
position in the target sequence and the amplicon size which is 561 bp. 
 
However, the presence of the human type I interferon (IFN) genes clustered on 
human chromosome 9p21 (Hardy et al., 2004) caused some difficulties in the 
design of specific set of primers for each gene. The 13 subtypes of interferon α 
found on chromosome 9 are: IFNA1, IFNA2, IFNA4, IFNA5, IFNA6, IFNA7, 
IFNA8, IFNA10, IFNA13, IFNA14, IFNA16, IFNA17, IFNA21. Figure 5.3 
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shows the alignment of the genes at the IFN locus which are individually 
separated and do not overlap.  
Therefore, the primers matched more than one target causing difficulties for 
analysis of the expression and the interpretation of the results obtained after 
amplification. Table 5.3 displays the percentage of similarity of the transcriptional 
sequences between the IFNA genes by using NCBI-BLAST. 
All the selected primers have been ordered from Sigma-Aldrich (UK) and each 
oligonucleotide was solubilised with DEPC water to a concentration of 100 µM, 
and was aliquoted in 0.2 ml tubes and stored at -20°C. 
Genes Primers (5’ to 3’) Tm (°C) GC (%) Primer design 
IFNB1 
 
F:            ATGACCAACAAGTGTCTCCTCCAAA 65 44  (Zhang et al., 
2004) 
R:            GTTTCGGAGGTAACCTGTAAGTCTG 61 48 
IFNW1 
F:            GCCCATGTCATGTCTGTCCT 61 55 Primer Express 
R:            GCAAGCAGGTCTCCAGGTGT 63 60 
IFNA21 
F:            GATCTGCCTCAGACCCACAG 61 60 Primer Express 
R:            GAGCCTTCTGGAACTGGTTG 60 55 
IFNA4 
F:            GCTGTGATCTGCCTCAGACC 61 60 Primer Express 
R:            GCTGTGATCTGCCTCAGACC 61 60 
IFNA7 
F:            CTGGGCTGTGATCTGCCTC 62 63 Primer Express 
R:            GGAACTGGTGGCCATCAAAC 63 55 
IFNA10 
F:            GATCTGCCTCAGACCCACAG 61 60 Primer Express 
R:            GAGCCTTCTGGAACTGGTTG 60 55 
IFNA16 
F:            ATCCCAATGGCCCTGTCC 63 61 Primer Express 
R:            TCAGGCAGGAGAAATGAGAGAT 60 45 
IFNA17 
F:            GTGATCTGCCTCAGACCCAC 61 60 Primer Express 
R:            GTCTTCTGGAACTGGTTGCC 60 55 
IFNA14 
F:            CAGCAGCATCTTCGGGATT 61 52 Primer Express 
R:            TGTGCCATGAGCATCAAAGT 60 45 
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Table 5.2:  List of the selected primers for the genes in the chromosomal region 
9p21 with melting temperature (Tm) of each primer and percentage of GC 
content. 
 
 
IFNA5 
F:            GATCTGCCTCAGACCCACAG 61 60 Primer Express 
R:            GAGCCTTCTGGAACTGGTTG 60 55 
KLHL9 
F:             AGTGACTGCCTTCCCTTGATAA            60 45 Primer Express 
R:            GCCGTTACCAAGGGACACTT 61 55 
IFNA6 
F:            GCTGAAGCCATCTCTGTCCTC 61 57 Primer Express 
R:            CTCACAGCCAGGATGGAGTCC      64 62 
IFNA13 
F:            GGACCTTGATGCTCCTGGCAC 66 62 Primer Express 
R:            CACAGCCAAGATGGAGTCCGC 67 62 
IFNA2 
F:            CTGGCACAGATGAGGAGAATC 60 52 Primer Express 
R:            GCTTCCAGGTCATTCAGCTGC 64 57 
IFNA8 
F:             TGCCAAAACCATGCTATGAA 60 40 D9S1712 
R:            CATCTGTAAGGGACTAGTGCCC 60 55 
IFNA1 
F:            CATACACCAGGTCACGCTTT 59 50 Primer 3 
R:            CACTAACCACAGTGTAAAGG 51 45 
IFNE1 
F:            GGCCATTCTCCATGAGATGC 63 55 Primer Express 
R:            GGTAATCATGGATCCTTCGG 59 50 
MTAP 
F:            GCCCACTGCAGATTCCTTTC 62 55 Behrmann et al., 
2003  
R:            CTGGGCAGCCATGCTACTTT 63 55 
CDKN2A 
F:            CATCAGTCACCGAAGGTCCT   60 55 D9S2060 
R:            AATGGACATTTACGGTAGTGGG   60 45 
CDKN2B 
F:            GCCTTTGCTCTTACTACA 48 44 D9S958 
R:           GTTCTTCCTCACATTTTA 45 33 
DMRTA1 
F:           GGTCTAATGGTGTCATTGGG 58 50 Primer Express 
R:           CAATGGCTTGGACCACATCC 64 55 
ELAVL2 
F:            CTCAGAACATGACACAGGAGG 58 52 Primer Express 
R:            CTGAACTTGGGCGAGCATAGG 64 57 
TUSC1 
F:            AGCCAAGACAGGCATGAGTT 60 50 Primer Express 
R:            CAGCTGTTCTTTCATATGTGGC 60 45 
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Figure 5.3: IFN genes alignment. Sequences alignment of the interferon genes at 
9p21, the other genes which do not produce a protein (red) are the pseudogenes. 
All the interferon genes have a single exon which is shown in the vertical lines.  
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Table 5.3: Summary of the similarities between the genes transcriptional 
sequences. This table summarises the similarities between the 13 genes of the IFN 
locus after using NCBI-Blast for each transcript. The homology is displayed as a 
percentage of coverage of the sequences, showing that some genes have up to 
100% similarities generating difficulties for designing the primers. For example 
the IFNA5 gene has a DNA sequence of 570 bp and displays a homology of 100% 
with most of the IFN subtype genes (A2, A4, A7, A10, A14, A16, A17 and A21). 
However, the IFNA1 mRNA sequence is not homologue at 100% to any of the 
IFN subtypes.  
 
 
 
 
 
 
 
IFN 
genes 
(%) 
IFNA1 IFNA2 IFNA4 IFNA5 IFNA6 IFNA7 IFNA8 IFNA10 IFNA13 IFNA14 IFNA16 IFNA17 IFNA21 
IFNA1 100 81 - 64 65 - - 78 74 80 74 80 74 
IFNA2 62 100 - 49 49 - 90 - 56 84 79 - 86 
IFNA4 - - 100 58 57 75 82 87 - 86 82 90 86 
IFNA5 99 100 100 100 99 100 - 100 99 100 100 100 100 
IFNA6 100 99 99 99 100 97 99 99 100 99 99 99 99 
IFNA7 - - 99 77 75 100 88 99 - 95 95 100 95 
IFNA8 - 99 78 54 54 62 100 78 - 92 90 91 92 
IFNA10 71 - 89 59 58 76 84 100 60 95 95 100 95 
IFNA13 99 87 - 80 80 - - 89 100 87 89 96 90 
IFNA14 83 94 94 73 72 90 96 94 72 100 94 100 94 
IFNA16 69 96 85 60 60 74 - 100 60 99 100 100 99 
IFNA17 71 - 90 58 57 75 95 99 64 - 95 100 95 
IFNA21 67 99 87 55 55 72 93 94 57 90 90 95 100 
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5.2.3. Reverse Transcription PCR (RT-PCR) 
 
Reverse transcription polymerase chain reaction is a sensitive method for the 
detection of mRNA transcription levels. The process traditionally involves two 
steps: the first step consists of the generation of the complementary DNA (cDNA) 
or first strand reaction, and the second step is the amplification of the cDNA by 
polymerase chain reaction (PCR). This method is widely used in molecular 
biology and is usually referred to as RT-PCR.  
Before commencing it is important to remove DNA contamination by treating the 
RNA with DNase that digests single and double-stranded DNA to 
oligodeoxyribonucleotides containing a 5‟ phosphate. After dilution of RNA to a 
concentration of 4 µg using DEPC treated water, 2 µl of 10X buffer (Sigma-
Aldrich, UK) and 0.5 µl of RNase Out which acts as an RNase inhibitor and 2 µl 
of  Deoxyribonuclease I (DNase I from Sigma Aldrich, UK). The final volume 
was 20 µl and was incubated at room temperature for 60 minutes. This was 
followed by adding stop solution by adding 2 µl of 25 mM EDTA that blocks 
DNase activity. The tubes were incubated for 15 minutes at 65°C, then put on ice. 
The first step of reverse transcription PCR is the generation of cDNA from RNA. 
The method found the most efficient for our study was the use of random primers 
(random hexamers) for first strand complementary DNA synthesis in order to 
obtain various random sequences along the mRNA. The other commonly used 
methods for cDNA synthesis are: gene specific primer pairs which amplify 
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exclusively the gene of interest and is mainly used for amplification of low 
abundance transcripts; and oligo (dt)-based priming.  
In PCR tubes, to 5 µl of DNase treated RNA were added the following, 1 µl of 
random primers at a concentration of 250 ng and 1 µl of 10 mM dNTP mix that 
was prepared by diluting 1 in 10 of the 100 mM stock of all four dATP, dCTP, 
dGTP, dTTP and mixing equal volumes of each. On each tube, a volume of 4 µl 
of DEPC water was added for a final volume of 20 µl. Once the tubes were spun 
briefly, they were incubated for 10 minutes at 70°C in a thermal cycler and then 
placed on ice. 
The following mix was added to the samples: 4 µl of 5X First-Strand Buffer  
[250  mM Tris-HCL (pH 8.3 at room temperature), 375 mM KCL, 15 mM 
MgCl2], 2 µl of 0.1 M DTT, 0.5 µl of RNase Out and 1 µl of SuperScriptIII 
(Invitrogen, UK), the total volume was made up to 20 µl by adding 0.5 µl of 
DEPC water. The tubes were incubated at 42°C for 50 minutes then at 70°C for 
15 minutes in a thermal cycler. Finally, the synthesised cDNA was placed on ice 
then stored at - 20°C, or processed directly for reverse transcription steps.  
The next step of the reverse transcription was PCR amplification, however prior 
to the amplification of specific genes it was important to check the synthesis and 
the quality of the cDNA, the gene GAPDH has been used for this purpose. 
Glyceraldehyde-3-phosphate
 
dehydrogenase (GAPDH) is one of the best known 
housekeeping genes expressed at very high levels. Hence, their amplification 
profile reaches significant level compared to the relatively low abundant RNAs 
studied.  
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The RT-PCR conditions vary from one gene to another according to the primer 
sets specifications, it was important to optimise the PCR conditions for each target 
gene by modifying cDNA concentration, cycle numbers, annealing temperature, 
MgCl2 concentration.  
However, the preparation was similar to all the genes with some changes 
depending on the cDNA concentration used, 17 µl of ReddyMix PCR Master Mix 
(1.5 mM MgCl2) (ABgene, UK) was added in PCR tubes. Then 1 µl of diluted 
forward primer (1/10 dilution) and 1 µl of diluted reverse primer (1/10 dilution) 
were added to the master mix. Finally, 1 or 2 µl of cDNA was added in the PCR 
tube specifically corresponding to the cell lines. 
For the present study, 3 control cell lines have been used for the gene expression 
analysis, a normal human fibroblast cell line (1BR.3) and two cancer cell lines: 
PC-3 (prostate cancer) and PB-1 (breast cancer).  
The expression analysis of the 23 genes of the 9p21 region was carried out in 12 
suppressor (S1 to S12) and 10 non suppressor hybrids (NS1 to NS10), UACC-903 
parental cell lines and three control cell lines (1BR.3, PC-3, PB-1) and a negative 
control (blank) where 1 µl of DEPC water was added instead of cDNA. 
The PCR cycle conditions used for most of the genes were as followed: 
The first step corresponded to „hot start‟ with a temperature at 94°C during 2 
minutes followed by 35 or 40 cycles of denaturation (94°C for 45 seconds), 
annealing step with a temperature that varies between 55 to 65°C depending on 
the gene (Table 5.3) for 45 seconds, and extension step at 72°C for 25 seconds. 
The final step consisted on a final extension for 5 minutes at a temperature of 
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72°C followed by an additional step at an indefinite time for short-term storage of 
the reaction. 
The PCR products generated by amplification were visualised by electrophoresis 
on a 1% agarose gel stained with ethidium bromide. The size of the amplicon was 
determined by using 1Kb plus ladder (Invitrogen, UK) (Figure 5.4). 
 
Figure 5.4: 1 KB plus ladder used as a marker to determine PCR products size. 
 
5.3. Results 
 
 
Reverse transcription PCR was carried out for 23 genes located at chromosome 
9p21. After extraction of the RNA using the TRIzol method and generating 
complementary DNA, expression of these genes has been assessed by PCR 
amplification. Each gene has been tested for expression in suppressor and non 
suppressor hybrids, the original parental tumourigenic UACC-903 melanoma cell 
line and three control cell lines: the normal fibroblast 1BR.3 cell line, the PC-3 
prostate cancer cell line and the PB-1 breast cancer cell line.  
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The house keeping gene GAPDH has been used as a control for checking the 
quality and quantity of synthesised cDNA by using the following primers:  
Forward 5‟ GAAGGTGAAGGTCGGAGT 3‟ and reverse 5‟ 
GAAGATGGTGATGGGATTTC 3‟. The PCR conditions to amplify GAPDH 
were as followed: The first step of GAPDH amplification was a hot start at 95°C 
for 5 minutes, then 30 cycles of 95°C for 45 seconds, 55°C for 45 seconds and 
72°C for 45 seconds. The final extension was at 72°C for 10 minutes followed by 
a final hold step for unlimited time at 4°C. The expected product size is 213 bp 
shown as a single band in Figure 5.5.  
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Figure 5.5: RT-PCR gel demonstrating the quality of the cDNA from all the 
samples using GAPDH primers set that generates a 213bp product. Amplified 
products were run on a 1% agarose gel stained with ethidium bromide.  
 
RT-PCR was performed for all the genes of the 9p21 region and each gene was  
tested for expression in 23 melanoma cell lines (parental, NS and S hybrids), 
1BR-3 normal fibroblast cell line and 2 cancer cell lines (PB-1 and PC-3). 
The optimisation of the PCR conditions was carried out for each gene, and the 
final annealing temperature specific to each gene is showed on Table 5.4.  
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Genes Annealing temperature (°C) Expected product size (bp) 
IFNB1 60 561 
IFNW1 60 151 
IFNA21 59 151 
IFNA4 59 151 
IFNA7 59 151 
IFNA10 60 151 
IFNA16 57 166 
IFNA17 57 158 
IFNA14 58 151 
IFNA5 59 151 
KLHL9 57 151 
IFNA6 59 212 
IFNA13 60 323 
IFNA2 51 239 
IFNA8 58 101 
IFNA1 60 176 
IFNE1 58 230 
MTAP 60 899 
CDKN2A 60 150 
CDKN2B 60 295 
DMRTA1 57 325 
ELAVL2 57 219 
TUSC1 60 139 
 
Table 5.4: Optimal annealing temperature (Ta) and expected amplicon size for 
the genes present in the chromosomal region 9p21.  
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The results of the amplification of a representative sample of genes in the 
suppressor and non-suppressor hybrid cell lines are shown below (Figure 5.6 to 
5.13). The RT-PCR products were analysed on 1 % agarose gel electrophoresis 
stained with ethidium bromide and visualised under UV transillumination.  
The non suppressor hybrids have been loaded on the top wells, and the suppressor 
in the bottom wells. Both top and bottom lanes had a negative control sample 
(blank) and positive sample (1BR-3, PB-1 and PC-3).  
 
 
 
 
 
 
 
 
 
 
Figure 5.6: The figure shows products of RT-PCR of the KLHL9 gene. The size 
of the products is 151 bp. KLHL9 was expressed in the UACC-903 parental cell 
line and all the NS and S hybrids as well as the 1BR-3 normal fibroblast, the PB-1 
breast cancer cell line and PC-3 prostate cancer cell line.  
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Figure 5.7: Amplification products of MTAP gene with bands at 899bp. 
Expression has been observed in all the hybrids, the parental cell line UACC-903 
and the controls cell lines. The intensity of the band was quite strong which can be 
an indication of the quantity of the amplified product.  
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Figure 5.8: RT-PCR of IFNA13 gene generating 323 bp products and is 
expressed in almost all the hybrids 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.9: RT-PCR products of the IFNE1 gene with product size of 230bp. The 
IFNE1 is expressed in all suppressor hybrids, and was not expressed in 4 of NS 
hybrids (NS2, NS3, NS5 and NS10).  
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Figure 5.10: Agarose gel electrophoresis after RT-PCR of the CDKN2A gene 
with product size of 150bp. CDKN2A was expressed in all suppressor hybrids at 
high levels but not in 4 of the non suppressor hybrids (NS3, NS5, NS7 and NS10). 
Expression the CDKN2A gene was very high in the control cell lines 1BR-3, PB-
1 and PC-3.  
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Figure 5.11: RT-PCR products of the CDKN2B gene with product size of 295bp. 
The CDKN2B is not expressed in 6 of the non suppressor hybrids and 5 of the 
suppressor hybrids. However, it is expressed in the parental cell line UACC-903. 
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Figure 5.12: RT-PCR of the gene IFNA1 with products of 176 bp. The IFNA1 
was expressed in NS7 only and not expressed in all other non suppressor hybrids.  
Amplification generated products in the 12 suppressor hybrids as well as the 
parental melanoma cell line UACC-903, and at high levels in the control cell lines 
1BR.3, PB-1 and PC-3. 
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Figure 5.13: Amplification products of the DMRTA1 gene with size of 325 bp 
expressed in both suppressor and non suppressors hybrids. The function of this 
gene is still unknown. 
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        Samples                      
 
 
 
 
Genes U
A
C
C
-9
0
3
 
1
-B
R
3
 
Non Suppressor Hybrids Suppressor Hybrids 
P
B
-1
 
P
C
-3
 
N
S
1
 
N
S
2
 
N
S
3
 
N
S
4
 
N
S
5
 
N
S
6
 
N
S
7
 
N
S
8
 
N
S
9
 
N
S
1
0
 
S
1
 
S
2
 
S
3
 
S
4
 
S
5
 
S
6
 
S
7
 
S
8
 
S
9
 
S
1
0
 
S
1
1
 
S
1
2
 
IFNB1                           
IFNW1                           
IFNA21                           
IFNA4                           
IFNA7                           
IFNA10                           
IFNA16                           
IFNA17                           
IFNA14                           
IFNA5                           
KLHL9                           
IFNA6                           
IFNA13                         / / 
IFNA2                           
IFNA8                           
IFNA1                           
IFNE1                           
MTAP                           
CDKN2A                           
CDKN2B                           
DMRTA1                           
ELAVL2 / / / / / / / / / / / / / / / / / / / / / / / / / / 
TUSC1                           
 
Table 5.5: Summary of the results of gene expression analysis carried out for the 
23 genes present in the 9p21 region in 10 non suppressor hybrids, 12 suppressor 
hybrids, the parental melanoma cell line UACC-903 and three control cell lines 
1BR-3, PB-1 and PC-3. The results were visualised on 1% agarose gel 
electrophoresis after RT-PCR.  
 
 
 
5.4. Discussion 
  = High level of expression      
 
     = Lower level of expression 
 
     = No expression             /  = not available 
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5.4. Discussion 
 
The gene expression analysis of the genes in the chromosomal region 9p21 was 
carried out in order to characterise potential tumour suppressor gene(s) involved 
in the development of cutaneous malignant melanoma. During the gene 
expression analysis, the pseudogenes have not been studied or analysed as they 
code for non functional proteins. Consequently, the study focused on the 
functional genes only. 
The 23 genes in the region 9p21 and several studies have showed the evidence of 
the presence of one or more tumour suppressor genes functioning independently 
of p16 which play a role in the development of CMM. Reverse transcription PCR 
was carried out individually for each gene after designing primer sets that match 
the target gene only. The synthesis of complementary DNA was performed using 
random primers after extraction of the RNA with TRIzol.  
 
IFN α genes 
 
The design of primer pairs was made difficult due to the presence of the IFN I 
cluster in the 9p21 region. The type I interferons are a family of cytokines that 
inhibit viral replication and cell proliferation and also activation of the immune 
system (Stark et al., 1998). The IFN cluster is located in the short arm of 
chromosome 9 and consists to date of 26 genes (13 IFNA, 1 IFNB, 1 IFNW and 
11 IFN pseudogenes) (Diaz et al., 1994). The IFNα locus consists of 13 subtypes 
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that are called IFNA1, IFNA2, IFNA4, IFNA5, IFNA6, IFNA7, IFNA8, IFNA10, 
IFNA13, IFNA14, IFNA16, IFNA17, IFNA21. These genes have high homology 
and similarity (Table 5.4) and most of the primers designed matched different 
genes of the IFN locus. Therefore, amplification of a specific target gene could 
result in the amplification of other IFN α genes. However, it was possible to 
design specific primers for the genes IFNA1, IFNA8, IFNA13 and IFNA14 by 
using STS markers selected in the genes. In addition, the genes which primers sets 
matched only a single target after using NCBI blast are: IFNB1, IFNW1, IFNA14, 
KLHL9, IFNA8, IFNA1, IFNE1, MTAP, CDKN2A, CDKN2B, DMRTA1, 
ELAVL2 and TUSC1.  
The RT-PCR results of the IFNA genes are displayed in the Table 5.5, the genes 
IFNA2, IFNA4, IFNA5, IFNA6, IFNA7, IFNA10, IFNA16, IFNA17 and IFNA21 
are expressed in all the suppressor and non suppressor hybrids, as well as the 
parental melanoma cell line UACC-903. These genes are also expressed at a 
higher level in the 1BR.3 fibroblast cell line, PC-3 prostate cancer cell line and 
PB-1 breast cancer cell line. Therefore, these genes are not considered as 
candidate TSG due to the fact that they expressed in all the cell lines. However, 
the availability of specific primer sets for each gene would have given more 
accurate results. 
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IFNA8 and IFNA14 
 
From the results of the amplification IFNA8 and IFNA14 are not candidate TSG 
genes because expression is observed in the 12 suppressor and 10 non suppressor 
hybrids with higher levels of expression in the control cell lines.  
 
IFNB1 
 
IFNB1 gene is expressed in all the cell lines and hybrids which can lead to the 
conclusion that interferon beta is not the candidate TSG. However, recent work 
from Kubo et al., 2008 demonstrated that IFNB1 has an anti-tumour effect on 
malignant melanoma; it inhibits proliferation and induces apoptosis on melanoma 
cells in vitro depending on the injected dose into the melanoma lesions. These 
observations depend among the cell lines so it is possible to conclude that gene 
expression analysis of IFNB1 gene should be tested in other melanoma cell lines.   
 
IFNW1 
 
IFNW1 is not considered as the candidate TSG because the expression was 
observed in almost all the non suppressor hybrids except for the NS4 sample, and 
was expressed in all the suppressor hybrids but not in the S12 sample.  
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KLHL9 
 
KLHL9 is not a potential TSG because it is expressed in all the control cell lines, 
the UACC-903 melanoma parental cell line and all the suppressor and non 
suppressor hybrids.  
 
IFNA13 
 
The gene IFNA13 is expressed in high levels in most of the hybrids and is not 
expressed in one suppressor hybrid. This gene was not tested in the PB-3 and PC-
1 cell lines but was expressed in UACC-903 parental cell line and 1BR.3 normal 
fibroblast. It can be concluded that the IFNA13 is not a potential TSG involved in 
the development of CMM. 
 
IFNA1 
The interferon IFNA1 is the potential candidate gene in this study. This gene was 
expressed in all of the hybrids which demonstrate tumour suppression in the soft 
agar assay. In addition it was expressed in only one of the non-suppressed 
hybrids. The expression of IFNA1 gene in only 1 of the non suppressor hybrids 
(NS7) is an indication that the IFNA1 may play a role in the suppression of 
tumourigenicity. Studies have demonstrated that interferon α is used in 
immunotherapy treatment of melanoma and it possibly induces mechanisms to 
inhibit the progression of the disease which remain unclear. The fact that IFNA1 
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is expressed in suppressor and not in non suppressor hybrids is a strong evidence 
that it plays a role in reducing tumourigenicity. 
 
IFNE1 
 
 Similarly to IFNA1 gene, IFNE1 was not expressed in 40% of the non suppressor 
hybrids (NS2, NS3, NS5 and NS10) and expressed in all the suppressor cell lines 
suggesting that it can also be a candidate TSG. However, the role of IFNE1 gene 
remains unclear. 
 
MTAP  
 
Methylthioadenosine phosphorylase plays a major role in polyamine metabolism 
and for the salvage of both adenine and methionine. MTAP catalyses the 
phosphorylation of methylthioadenosine (MTA) which acts as an inhibitor of 
polyamine aminopropyltransferases and methyltransferases (Behrmann et al., 
2003). 
MTAP gene has attracted a lot of attention because of its location next to INK4 
locus. Findings indicated that MTAP and the p16 TSG are codeleted in many 
cancers (Nobori et al., 1996) and that a significant down-regulation of MTAP 
expression was observed in many melanoma cell lines (Behrmann et al., 2003).  
The MTAP gene is expressed at high levels in both suppressor and non suppressor 
hybrids and the control cell lines, and also UACC-903 melanoma cell line. 
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CDKN2A and CDKN2B 
 
The INK4 locus genes coding for p16 and p15 were expressed in some of the 
suppressor and non suppressor hybrids. However, the p16 gene is mutated and 
therefore non functional in the UACC-903 cell line as mentioned in Trent et al., 
1990.  Loss of p16 can consequently lead to the loss of p15 gene because both 
genes can be simultaneously deleted or mutated. It has been demonstrated that 
these two genes are codeleted in a high proportion of established human cancer 
cell lines (Kamb et al., 1994). 
 
DMRTA1 
 
RT-PCR of this gene showed high levels of expression of this gene in all the 
suppressor and non suppressor hybrids. The DMRTA1 function remains 
unknown. 
 
ELAVL2 
 
Despite testing different PCR conditions such as the annealing temperature, cycle 
number, MgCl2 concentration, but no RT-PCR products were detected for this 
gene. This gene is also referred to as Hel-N1 (human elav-like neuronal protein 
1), an RNA-binding protein expressed in neurons (King et al., 1994) suggesting 
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that this gene might be cell specific and unlikely to be a primary target for tumour 
suppressor.  
 
The results provide evidence that IFNA1 and IFNE1 are likely to be potential 
tumour suppressor genes involved in the development of melanoma. Expression 
of IFNA1 and IFNE1 has been detected in all the suppressor hybrids and some of 
the non suppressor hybrids only. Reverse transcription PCR is a qualitative 
method to detect genes expression but does not give an indication of the precise 
levels of expression. Real time quantitative PCR approach has been utilised in 
order to measure the level of expression of the IFNA1 and IFNE1 genes in the 
different hybrids. 
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CHAPTER 6 
 
 
DETERMINATION OF EXPRESSION LEVELS OF 
CANDIDATE MELANOMA TUMOUR 
SUPPRESSOR GENES USING QUANTITATIVE 
PCR 
 
 
6.1. Introduction 
 
PCR is considered as one of the most important techniques for the detection of 
any nucleic acid sequence (RNA or DNA). Standard PCR allows the generation of 
a large number of identical copies of a target sequence for different purposes such 
as the detection of expression of a gene. The products are detected at the final 
phase of the amplification using agarose gel and viewed using a transilluminator. 
However, the standard PCR method has some limitations. For example, the results 
obtained are based on the size of the amplicon which may not be very precise as it 
does not measure the amount of amplified products. Therefore, quantification of 
the amplified nucleic acid can be difficult because the PCR generates the same 
amount of product independently of the initial amount of template molecules. 
Therefore, the results are size-based only and quantitative data cannot be 
obtained. 
 
6 
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This limitation was resolved in 1992 by Higuchi and colleagues with the 
development of real-time PCR. Real-time polymerase chain reaction also called 
quantitative PCR (qPCR) has become a very useful method for the quantification 
of mRNA (Bustin, 2000).  
Typical uses of real-time PCR include pathogen detection, gene expression 
analysis, single nucleotide polymorphism (SNP) analysis, analysis of chromosome 
aberrations and recently protein detection by real-time immuno PCR (Kubista et 
al., 2006). Also, measurements of DNA copy number which is known as absolute 
quantification real-time PCR is possible (Bustin, 2000).  
In real-time PCR, the amount of amplified DNA is proportional to the cycle 
number and the product formed is detected, quantified and monitored in real time.  
The DNA is measured using fluorescent reporter dyes (Higuchi et al., 1993) that 
bind to the double stranded DNA formed, the amount of product accumulates as 
the fluorescent signal increases exponentially. A number of probes and dyes are 
available for real-time PCR; in the initial quantitative assay the common nucleic 
acid stain EtBr was used and the fluorescence was detected upon intercalating into 
the double stranded DNA (Higuchi et al., 1993). However, classical intercalators 
may interfere with the polymerase reaction, therefore asymmetric cyanine dyes 
such as SYBR Green and BOXTO have become more popular (Zipper et al., 
2004). These agents bind to the minor groove of the DNA double helix and have 
no fluorescence when free in solution but they are brightly florescent when they 
bind to double stranded DNA, and the fluorescence increases with the amount of 
double stranded product formed during the PCR reaction. These dyes are 
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considered as non-specific reporters and they give fluorescent signal when they 
bind to any double stranded DNA, including primer dimers which may interfere 
with the formation of target products, leading to the generation of errors in the 
results. It is therefore important to check for the formation of primer dimers by 
adding a melting curve analysis after the amplication (Kubista et al., 2006). The 
melting or dissociation curve consists of increasing the temperature gradually 
until the florescent signal drops when the temperature is reached at which the 
double stranded DNA separates, therefore the dye is detached and the florescent 
signal stops suddenly (Ririe et al., 1997). The temperature at which the two 
strands of the target DNA separate is known as the melting temperature (Tm), and 
the primer dimers are usually shorter than the amplicon, they melt at a lower 
temperature that the Tm and they can be easily detected during a dissociation 
curve analysis. 
In addition to non-specific detection using DNA binding probes like SYBR Green 
I, there are specific probes which detect specific targets. The detection is done 
with oligonucleotide probes labelled with two dyes: a reporter fluorescent and a 
quencher dye. Examples of probes with two dyes are the Taqman probes and 
Molecular Beacons (Holland et al., 1991; Tyagi and Kramer, 1996). 
As mentioned previously, the fluorescent signal increases gradually as the product 
accumulates, until it reaches a point where it saturates. Saturation of the signal is 
due to the fact that some reagents or reaction components may run out, such as 
primers, the reporter or dNTPs (Kubista et al., 2001). It is important to know that 
during real-time PCR a particular threshold fluorescent signal level is reached at a 
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certain number of amplifications which is shown in the samples‟ response curve. 
It is the point where the fluorescent signal first rises above a defined background 
fluorescence (Nolan et al., 2006). The number of cycles required to reach this 
threshold is represented as the Ct value (cycle threshold) and this value is 
inversely proportional to the amount of amplified DNA in the sample. In other 
words, the lower the Ct value is, the greater is the amount of target DNA in the 
sample. This threshold is usually selected automatically by the thermal cycler 
software but it can be set manually by the user.  
Prior to gene expression measurements it is worth noting that the mRNA should 
be copied to cDNA by reverse transcription (RT-PCR), this step is critical for the 
accuracy and the sensitivity of the quantification. Also, in order to increase the 
accuracy, the real-time PCR is performed using duplicates or triplicates for each 
analysed sample.  
Real-time PCR is very useful quantification method and has been proven to be 
successful in various molecular biology applications and this quantification of 
DNA can be either relative or absolute. Absolute quantification allows the precise 
determination of copy number per cell and total RNA concentration. In contrast, 
relative quantification compares the expression of a gene to that of a calibrator 
gene. In other words, the target Ct value is compared directly with the calibrator 
Ct and is monitored and evaluated as containing either more or less mRNA 
(Bustin, 2000).  
In the present study, relative quantification has been used where cDNA samples 
prepared from suppressor and non suppressor hybrids for the genes IFN epsilon 1 
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(IFNE1) and IFN alpha 1 (IFNA1) have been monitored for expression levels. 
These two genes were selected because our basic expression analysis described 
and discussed in chapter 5 demonstrated differential expression levels in UACC-
903 melanoma cell hybrids with an additional chromosome 9a. Thus in this study 
they are regarded as potential tumour suppressor genes. For each gene, two 
separate 96 wells plates were prepared, one for the analysis of expression levels in 
the non suppressor hybrids along with the GAPDH gene, and the second 96 wells 
plate for the suppressor hybrids cDNA samples as well as GAPDH gene.  
 
6.2. Materials and methods 
 
6.2.1. Real-time PCR 96 wells plate set-up and samples preparation 
 
The procedure for real-time PCR follows the principles of standard PCR. The 
samples were prepared by pipetting the PCR mastermix (see below) into a 96 
wells plate MicroAmp™ Fast Optical 96-Wells Reaction Plate with Barcode 0.1 
ml (Applied Biosystems, UK) kept on ice. Each reaction was performed in 
triplicate and  the mix consisted of 1µl of forward primer diluted 1/10 in DEPC 
water and 1 µl of reverse primer diluted as well, both primers were added in 11 µl 
of SYBR green (Applied Biosystems, UK) and 11 µl of DEPC water. Finally 1 µl 
of specific cDNA was added in each sample, except for the non template control 
(NTC) sample where 1 µl of DEPC water was added instead of the cDNA and 
was considered as a negative control for the experiment in order to check for non 
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specific signal arising from primer dimers or contamination. After putting 25 µl of 
each sample in the wells, the plate was covered with a MicroAmp™ optical 
adhesive film (Applied Biosystems, UK) and sealed tightly to avoid evaporation. 
The plate was then centrifuged for 1 minute at 3000rpm, and loaded into the real-
time PCR system. 
6.2.2. Real time PCR program set-up  
The real time PCR system used in the present study is the ABI Prism
®
 7900 HT 
real-time PCR instrument (Applied Biosystems) which is a powerful platform for 
quantitative PCR analysis. The machine is connected to a PC and uses the SDS 
2.1 software from Applied Biosystems. After opening the program, the selected 
assay is relative quantification which determines the changes in mRNA levels of a 
gene across multiple samples and evaluates the expression by comparing to the 
levels of an internal control RNA.  
The probe used in the current study was SYBR Green I (Applied Biosystems, UK) 
and two detectors were added in the program: GAPDH detector was assigned as 
endogenous control which is usually used as a reference for normalization during 
real-time PCR, and IFN detector which was assigned as target. It is important 
noting that the same name of samples should be assigned for the triplicates 
(Figure 6.1). 
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Figure 6.1: Real-time PCR 96 wells plate set-up. 
 
 
Two different plates have been prepared for the gene expression analysis of the 
IFNE1 and IFNA1 genes because of the high number of samples and control cell 
lines, the non suppressor and suppressor hybrids cell lines of UACC-903 were run 
on separate 96 wells plates as illustrated in Figures 6.2 and 6.3. 
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Figure 6.2: Set up of the 96 wells plate for 10 non suppressor hybrids as well as 
the parental melanoma cell line UACC-903 and the three control cell lines 1BR.3, 
PC-3 and PB1. A negative control sample noted NTC (non template control) 
containing water instead of cDNA. 
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Figure 6.3: Set up of the 96 wells plate for 12 suppressor hybrids. The 
control cell line PB1 was not added. 
 
The amplification programs for the IFNE1 and IFNA1 were the same as the one 
used during the RT-PCR for gene expression analysis as seen in the previous 
chapter. However, the cycle number was increased to 50 cycles in order to 
determine more clearly the exponential phase as it is the optimal point for 
analysing the data (Figure 6.4). After loading the 96 wells plate in to the real-time 
thermal cycler, the machine was connected to the computer and the program run 
for 1 hour and 30 minutes. An additional step was added after the real-time 
amplification run was completed, which was the dissociation curvestage (Figure 
6.5), this step is important because SYBR Green binds to any double stranded 
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DNA molecule including primer dimers which can interfere with the target 
molecules. 
 
 
Figure 6.4: Real-time PCR cycle conditions set up. The different stages of 
amplification can be set with temperature and time as well as the number of 
cycles. 
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Figure 6.5: Dissociation curve stage conditions. The temperature is increased 
progressively from 60 to 95°C, the double stranded DNA strands will melt when 
the temperature reached the Tm. The amplicon produced from the targeted 
product is longer and will melt at a higher temperature than primer dimers (PD). 
The x axis represents the temperature (°C) and on the y axis is the negative 
derivative of the fluorescence emitted by each sample during the melting curve 
analysis.   
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6.3. Results 
6.3.1. Interferon epsilon 1 (IFNE1) 
 
Although the role of IFNE1 gene remains unknown, the structure and mRNA 
expression pattern of IFNE1 suggest that it may have a function distinct from 
those other members of type I IFN which are cytokines that play a role in assisting 
the immune response. Moreover, from the standard RT-PCR results displayed in 
chapter 5, the gene IFNE1 is believed to be one of the candidate genes that might 
be involved in the development of cutaneous melanoma. The IFNE1 gene was 
expressed in all the suppressor hybrids but not in some of the non suppressor 
hybrids (not expressed in NS2, NS3, NS5 and NS10).  
Analysis of gene expression by real-time PCR using relative quantification results 
in monitoring the levels of mRNA of the target IFNE1 gene in the suppressors and 
the non suppressor hybrids as well as for the GAPDH gene which was considered 
as an endogenous control used in order to normalise the qPCR.  
 
 6.3.1.1. qPCR of non suppressor hybrids for IFNE1 gene 
 
A relative quantification was carried out for the IFNE1 target gene and it 
consisted of analysing the changes in fluorescence signal cycle by cycle. Each 
sample was tested in triplicate for IFNE1 target gene and also for GAPDH 
endogenous control gene.  
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The samples were prepared and loaded in the 96 wells plate as shown previously 
in Figure 6.2. After approximately two hours of amplification, the data were 
collected for analysis under the program name ΔΔCt study. The results are 
displayed as an amplification plot representing the measurement of the fluorescent 
signal for each sample in each well versus the cycle number as displayed in the 
Figure 6.6. The graphs showed in (a) are the amplification curves on a linear scale 
where Rn (normalised reporter signal) represents the fluorescence emission 
intensity at each cycle number. This amplification curve is characterised by three 
distinct regions corresponding to the progression of the PCR that are viewed more 
clearly in a logarithmic scale as shown in Figure 6.6 (b). An exponential phase 
which is a cycle range of high precision characterised by constant amplification 
efficiency and the first detectable rise in fluorescence occurs during this phase.  
A linear phase characterised by a decrease of the amplification efficiency due to a 
low concentration of one of the samples components. The third and final phase is 
the plateau where the amplification stops and the Rn signal remain relatively 
constant (Theory of operation, Applied Biosystems 7900HT manual).  
The crossing points of the threshold line in the exponential phase of the curve are 
the Ct values as shown in Figure 6. 6, it is possible to see that the average Ct 
values for the GAPDH gene samples is around 17 cycles, and the average Ct 
value for the IFNE1 gene is approximately 35 cycles. This observation shows that 
the levels of mRNA of the gene IFNE1 is less abundant than the ones of GAPDH 
genes. This is not surprising as it is well known that GAPDH is a housekeeping 
gene expressed in abundance. The NTC negative controls containing no input 
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cDNA are shown as background under the threshold red line. For these samples, 
the Rn curves appear as a flat line below the fluorescent signal detection limit. 
However, we can observe on the Figure 6.6 that the lines corresponding to the 
NTC samples tend to be less flat towards the end of the amplification which can 
be due to the accumulation of primer dimers because real-time PCR is extremely 
sensitive technique and amplification signals can be detected even if they are very 
low.  
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(a) 
 
(b) 
 
Figure 6.6: Amplification curves for non suppressor hybrids expression levels analysis 
for both IFNE1 gene (blue and purple) and GAPDH gene (green colour). (a) Linear scale 
of the amplification plot for non suppressor hybrids, on the y axis is ΔRn (normalised 
Reporter signal) which is the fluorescence intensity and the cycle numbers are on the x 
axis. (b) The logarithmic view of the amplification plot shows three phases as well, the 
exponential phases for IFNE1 (purple) occurs later than the one of GAPDH (green) 
indicating a difference of mRNA concentration between both genes.   
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The relative quantification of the expression of the genes was given  by  
measuring each individual relative quantification (RQ) value which allows the 
comparison of the levels of cDNA of the target gene and therefore gene 
expression level in each hybrid, to a calibrator which is a single reference sample 
used as the basis for the expression level. In the present study, the calibrator was 
the control normal dermal fibroblast cell line 1BR.3 and the aim of this analysis 
was to determine whether the levels of expression of the IFNE1 gene in each one 
of the suppressor as well as the non suppressor hybrids was more or less than the 
amount of mRNA of the IFNE1 gene in the control cell line 1BR.3. Levels of 
expression of all the non suppressor hybrids and the UACC-903 parental 
melanoma cell line were lower than the calibrator 1BR.3 which is set here at one. 
However, the expression of the IFNE1 gene in the two other cancer cell line was 
higher than in normal fibroblasts cell line 1BR.3 (Figure 6.8). 
 
6.3.1.2. qPCR of suppressor hybrids for IFNE1 gene 
 
Real-time PCR was also carried out for the suppressor hybrids and the samples 
were placed unto the 96 wells plate as explained in Figure 6.4. Twelve suppressor 
hybrids were tested in order to assess the expression levels of the IFNE1 gene also 
in the UACC-903 parental melanoma cell line and one of the PC-3 prostate cancer 
cell line.  The amplification plots in both linear and logarithmic views are shown 
in Figure 6.7. 
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(a) 
 
(b) 
 
Figure 6.7: Amplification plot for IFNE1 suppressor hybrids. (a) the linear view 
of PCR curve and (b) is the logarithmic view of amplification plot. The 3 lines 
which are between the two major groups of curves (green and yellow curves-
GAPDH on left and purple curves of right-IFNE1) represent the PC-3 sample 
triplicate and the flat lines are the NTC samples. 
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The gene expression plot of the suppressor hybrids for the IFNE1 gene is 
displayed in Figure 6.8. By taking 1BR.3 sample as the calibrator, we can see that 
all the levels of gene expression were below the calibrator except for the prostate 
cancer cell line where the IFNE1 is highly expressed.  
By taking the individual RQ values for each sample from suppressor and non 
suppressor hybrids it was possible to draw a graph for the expression of the 
IFNE1 gene. The RQ value is the calculated relative quantity of the sample 
expressed as a multiple of the calibrator. In other words, it represents the fold 
change of the level of expression compared to the calibrator. In the present work, 
the calibrator 1BR.3 level of expression was set to the value of 1 (Figure 6.8). An 
impaired t-test was carried out for the expression levels of the IFNE1 gene, the 
results of the test suggests that the difference of RQ values between the two types 
of hybrids is non-significant as the calculated p value was 0.135.  
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Figure 6.8: Gene expression levels of the non suppressor and suppressor hybrids 
which are below the 1.BR3 calibrator level except for PC3 and PB1 cell lines. By 
comparing the relative quantification values between the two types of hybrids, it 
appears that IFNE1 is expressed as higher amount in the non suppressor than the 
uppressor hybrids.  
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6.3.2. Interferon alpha 1 (IFNA1) 
 
Similarly to the IFNE1 gene, from the standard reverse transcription PCR carried 
out for the constructed suppressor and non suppressor hybrids, the IFNA1 might 
be a candidate gene which can play a role in the development of cutaneous 
malignant melanoma. In fact, expression of this gene has been detected in all the 
suppressor hybrids and in only one the non suppressor hybrids (NS7) (figure 
6.10). Real-time PCR has been chosen as a method to measure the levels of 
expression of the interferon alpha 1 gene in the different constructed hybrids, as it 
a highly sensitive method able to detect very low levels of double stranded DNA.  
 
6.3.2.1. qPCR of non suppressor hybrids for IFNA1 gene 
 
The non suppressor hybrids have been tested in order to quantify the expression of 
the IFNA1 gene. The 96 wells plate was prepared in the same manner as for the 
IFNE1. The amplification plot at a logarithmic scale is shown below (Figure 6.9). 
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Figure 6.9: Logarithmic view of the amplification plot of the non suppressor 
hybrids for the GAPDH (green curves) and IFNA1 genes (blue/purple curves). 
Most of the IFNA1 curves are flat which indicates that no fluorescent signal was 
detected.   
 
 
 
Expression levels plot was also available. As for the analysis of expression levels 
for the gene IFNE1, the calibrator chosen was 1BR.3 normal fibroblast cell line. 
Therefore, the levels of expression of the non suppressor hybrids for the IFNA1 
gene were compared to the one of 1BR.3 by measuring individual RQ values 
(Figure 6.12).   
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6.3.2.2. qPCR of suppressor hybrids for IFNA1 gene 
 
 
Figure 6.10: Logarithmic view of the amplification plot of the suppressor hybrids 
for the GAPDH (green) and IFNA1 genes (blue/purple).  
 
As shown in the above figures, the level of expression of the IFNA1 between the 
suppressor and the non suppressor hybrids show significant differences. 
Therefore, additional real-time PCR have been carried out in order to compare the 
relative quantification of both suppressor and non suppressor hybrids. In doing so, 
a 96 wells plate was prepared with duplicate of non suppressor and suppressor 
hybrid cell lines, the UACC-903 parental melanoma cell line, the 1BR.3 normal 
fibroblast cell line and the PC-3 prostate cancer cell line (Figure 6.10).  
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Figure 6.11: Set-up of suppressor and non suppressor hybrids for IFNA1 gene. 
 
Individual relative quantification (RQ) values for a set of suppressor and a set of 
non suppressor hybrids have been measured for each sample by taking 1BR.3 as 
the calibrator which RQ value was set at 1 as displayed in Figure 6.11.  By taking 
the individual RQ values for each sample from suppressor and non suppressor 
hybrids it was possible to draw a graph for the expression of the IFNE1 gene. The 
RQ value is the calculated relative quantity of the sample expressed as a multiple 
of the calibrator. In other words, it represents the fold change of the level of 
expression compared to the calibrator. In the present work, the calibrator 1BR.3 
level of expression was set to the value of 1. 
Statistical analysis of IFNA1 levels of expression between the S and NS hybrids 
resulted on a p value of 0.321 which suggests that there is no significant 
difference between the two sets of RQ values. Although, there is not a significant 
difference, some of the suppressor hybrids show to highly express INFA1.  
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Figure 6.12: Gene expression levels of the non suppressor and suppressor hybrids 
which are below the 1.BR3 calibrator level except for PC3 prostate cancer cell 
line and for one of the suppressor hybrid (S4). Most of the RQ values of the 
suppressor hybrids are higher than the ones of the non suppressor hybrids.  
 
A qualitative comparison of non-quantitative RT-PCR (Figure 5.12) with results 
from quantitative real-time PCR (Figure 6.12) for the expression analysis of 
IFNA1 has been carried out and showed that the NS7 sample, which is the only 
expressed hybrids among the non suppressor hybrids, has the highest RQ values 
when compared with the other non suppressor hybrids. The RQ values of the other 
hybrids were much lower than the RQ of NS7 and were therefore not detectable 
using standard PCR.  However, the suppressor hybrids did not show clear 
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correlation as some intense bands of some samples such as S1, S3, S9 and S11 did 
not have display high levels of expression of the IFNA1 gene. 
6.4. Discussion 
The aim of performing real-time PCR in this study was to measure the levels of 
expression of the genes IFNE1 and IFNA1 in the suppressor and non suppressor 
constructed hybrids. Gene expression analysis using standard RT-PCR revealed 
that the IFNE1 and IFNA1 genes might be the candidate tumour suppressor genes 
involved in the development of cutaneous malignant melanoma, this suggestion 
resulted from the expression of these genes in all of the suppressor hybrids and 
only some of the non suppressor hybrids.  
Real-time PCR is a highly sensitive method for quantitative reverse transcription 
PCR of mRNA levels from genes. Applying this method for the expression of the 
genes IFNE1 and IFNA1 showed different profiles of level of expression between 
the suppressor and non suppressor hybrids. Firstly, the cDNA amounts were 
measured between non suppressors using GAPDH as an endogenous control. On a 
second 96 wells plate, suppressor hybrid samples were assessed for level of 
cDNA as well which resulted in amplification plots showing that cDNA levels of 
the genes IFNE1 and IFNA1 were low compared to the cDNA levels of the 
GAPDH housekeeping gene (Figures 6.6, 6.7, 6.9, and 6.10). However, this 
observation was not surprising as it is known that housekeeping genes transcripts 
are abundant and their expression remains constant in the cells and tissues under 
investigation (Barber et al., 2005). The fluorescent signal for the GAPDH gene 
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was detected in first and the average Ct value was around 17, which means that 
the exponential phase of amplification started from the cycle number 17. On the 
other hand, the average Ct values for IFNE1 and IFNA1 were approximately 30 
and 35 respectively.  
Relative quantification (RQ) of the levels of mRNA was given by setting the 
1BR.3 fibroblast cell line as a calibrator where its RQ value was 1. This reference 
sample is used to measure the fold change of levels of expression, which means 
that if the RQ value is superior to 1 the mRNA level of the target gene is higher 
than the one of 1BR.3 and vice versa.  
The results obtained for the IFNE1 gene expression levels show that there was no 
major difference in the amount of mRNA between the suppressor and non 
suppressor hybrids, and that all the RQ values were below the one of the 
calibrator 1BR.3.  From the results presented in figure 6.8 it is possible to say that 
no significant difference in the amount of cDNA for the IFNE1 gene between the 
suppressor and the non suppressor hybrids. Despite the fact that standard RT-PCR 
resulted in the absence of expression of this gene in 4 out of 10 of the constructed 
non suppressor hybrids. Real-time PCR data for the analysis of levels of IFNE1 
transcripts illustrate that: (a) IFNE1 is expressed at high levels in the human 
prostate cell line (PC-3) and breast cancer cell line (PB-1) compared to its 
expression in the 1BR.3 fibroblast cell line, (b) IFNE1 gene is expressed at low 
levels in both the suppressor and non suppressor hybrids, (c) there is no 
significant differences in the expression of the IFNE1 gene in the hybrids.  
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Consequently, it is suggested that the IFNE1 gene might not be a candidate 
tumour suppressor gene involved in the development of CMM. The interferon 
epsilon 1 gene has been recently identified (Hardy et al., 2004) and its function 
remains unclear but it believed to have a different role than the others type I 
interferons which are cytokines with pleiotropic activities such as inhibition of 
viral replication, cell proliferation and activation of the immune system (Hardy et 
al., 2004). This difference of function results from the fact that IFNE1 gene has 
limited homology to other type I IFN genes. Also, their ability to bind to the type I 
IFN receptor is unknown. Hence, it is difficult to establish how IFNE1 can 
suppress tumourigenicity and if it deletion of this gene affects the development of 
CMM.  
In the case of the interferon alpha 1 (IFNA1) gene, real time PCR was performed 
in order to estimate the levels of expression in the two types of constructed 
hybrids as well as in other control cell lines. Similarly to the analysis carried out 
for the IFNE1 gene, levels of cDNA of the IFNA1 gene were compared to the 
GAPDH endogenous control and the relative quantification values were 
monitored. The amplification plots for some of the samples were almost flat as 
shown in Figures 6.9 and 6.10. The fluorescent signal was weak which can be 
interpreted as an indication of the presence of extremely low levels of dsDNA of 
the target gene or absence of amplification of the IFNA1 target gene.  
As illustrated in Figure 6.12, the relative quantification values for the IFNA1 gene 
in the suppressor hybrids were high when compared to the RQ values of the non 
suppressor hybrids. As a result, these data provide evidence that there is a 
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measurable difference of expression between the two types of hybrids. Expression 
of IFNA1 gene is higher in the suppressor than its expression in the non 
suppressor hybrids.  This observation provides tantalising evidence that the 
IFNA1 gene might be a candidate tumour suppressor gene involved in the 
pathogenesis of cutaneous malignant melanoma. The interferon alpha 1 gene is 
widely used in the treatment of specific types of tumour including melanoma. This 
immunotherapeutic agent is a cytokine exhibiting a potential anti-tumour effect 
and is used mainly in phase II and III melanoma patients. In addition, it has been 
suggested that IFNA1 might induce other tumour suppressor genes. For instance, 
IFNA1 anti tumour action has been proven by the fact that it induces the 
transcription of the p53 gene (Takaoka et al., 2003). Furthermore, the same 
researchers show that induction of the p53 gene by IFNA1 and IFNB1 contribute 
to tumour suppression but the mechanism(s) by which IFNA1 induces p53 is (are) 
still unclear. In order to confirm the involvement of IFNA1 in the development of 
melanoma, it would be possible to use siRNA knock down against IFNA1 and 
analyse its effects on tumourigenicity. Plasmid vector expressing appropriate 
small interfering RNAs of IFNA1 could be readily transfected into the parental 
tumourigenic UACC-903 cells. Published evidence suggests the knockdown of a 
targeted gene occurs within few hours and persists within less than one week 
(Bartlett and Davies, 2006). While this approach is possible, it would be difficult 
to assay for tumourigenicity by soft agar since these assays monitor colony 
growth over 2-3 weeks; by which time the transient effect of siRNA knockdown 
would have passed. Another informative approach would be to analyse IFNA1 
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protein expression using western blotting in cells taken at different stages of 
melanoma progression in tumours from patients would provide an indication of 
changes of expression occurring in CMM as no data has been provided yet 
relating the expression of IFNA1 during tumour progression.  
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CHAPTER 7 
 
C SUB-CLONING AND CHARACTERISATION OF 
IFNA1 GENE 
 
7.1. Introduction 
 
Although the anti-proliferative and pro-apoptotic mechanisms of interferon alpha 
(IFNA1) which have been recognised, its antitumour effects are not entirely known. 
Interferon alpha is a cytokine that displays anti-viral and immunomodulatory 
activities, and it is the most used type of cytokine being used as a therapy for the 
treatment of different types of cancer including some haematological malignancies 
and solid tumours such as melanoma (Ferrantini and Belardelli, 2000 ). Despite the 
wide clinical use, it is still unclear whether IFNA therapy is an effective strategy in 
melanoma therapy and more importantly the involvement of the IFNA1 gene in the 
pathogenesis of cutaneous melanoma remains to be fully established. After the 
identification of the IFNA1 gene as the potential candidate tumour suppressor gene in 
melanoma in the present study, the next step undertaken was the expression of the 
IFNA1 cDNA in the UACC-903 using an expression vector to evaluate suppression of 
tumourigenicity by anchorage independent growth and real-time PCR. These series of 
experiments aim to further determine the role of IFNA1 as a potential suppressor gene 
in melanoma. 
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7.2. Materials and methods 
 
The cell line used for the sub-cloning experiment was the normal dermal fibroblast 
1BR.3 described previously in Chapter 2. After isolation of IFNA1 RNA using 
TRIzol method (see section 2.6) and using reverse transcription method to obtain 
complementary DNA, and finally amplification IFNA1 cDNA (described in section 
5.2.3), the amplification product was cloned into a vector as described in the sections 
below: 
 
7.2.1. Preparation of LB Agar plates  
 
The first step for the IFNA1 cDNA cloning consisted of the transformation step of the 
plasmid cDNA. In doing so, agar plates have been prepared by weighing out the 
following: 10 g of bacto tryptone, 5 g of bacto yeast extract, 10 g of sodium chloride 
and 15 g of bacto agar and dissolving them in 950 ml of distilled water. After 
autoclaving the bottle at 121°C for 15 minutes, the hot agar bottle was placed in a 
water bath set at 55°C and 100μg of ampicillin per ml of agar was added from 
10mg/ml of stock solution. The bottle was swirled in order to mix the ampicillin and 
poured quickly into the plates (P-110 Nunclon, Fisher Scientific). The lids of the 
plates were flamed using a Bunsen burner and the plates were covered partially with 
their lid for the agar to set normally after 30 minutes. The plates were wrapped into 
cling film and stored at 4°C for no longer than one month.  
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7.2.2. Cloning of PCR products 
 
The TOPO TA cloning
®
 Kit (Invitrogen, UK) was used for the direct insertion of the 
IFNA1 PCR product into a plasmid vector for sequencing. The plasmid vector 
(pCR
®
4-TOPO
®) was supplied linearised with single 3‟ thymidine (T) overhangs for 
TA cloning and topoisomerase covalently bound to the vector. It also uses T7 and T3 
primers to allow for sequencing of + and – strands (Figure 7.1). 
 
Figure 7.1: The pCR®4-TOPO® vector displaying 3‟ T overhangs and the T7 and T3 
primers as well as the EcoR1 sites flanking the cloning site that simplify excision of 
cloned PCR products (Invitrogen, UK)  
(http://products.invitrogen.com/ivgn/en/US/adirect/invitrogen?cmd=catProductDetail
&entryPoint=adirect&productID=K457502&messageType=catProductDetail). 
 
Chapter 7: Sub-cloning and characterisation of IFNA1 gene  
       Page 153
   
 
 
The total ligation mixture was prepared by adding 1 μl of salt solution and 1 μl of 
vector solution provided in the kit, 2 μl of DEPC water was added as well as 2 μl of 
PCR product resulting from the amplification of IFNA1 cDNA.  The ligation mixture 
was then incubated at room temperature for 5 minutes and 2 μl were taken and added 
into the competent cells that were thawed on ice. The tubes were mixed gently 
without retro-pipetting as it might shear the DNA TA ligation), and incubated on ice 
for 15 minutes. The cells were put for 30 seconds in a water bath at 42°C to create a 
heat shock, and transferred immediately on ice. After that, 250 μl of warm SOC TOP 
10 medium was added into the tubes that were then placed into a shaker set at 37°C 
for an hour at 200rpm. After the shaking step, 50 μl and 100 μl of the plasmid were 
spread onto the pre-warmed LB agar plates containing 100 μg/ml of ampicillin. The 
plates were left to dry for approximately 10 minutes and placed into the 37°C 
incubator. The colonies were observed from the next day, and approximately 8 
colonies were picked and spread onto an agar plate that was divided into 8 parts by 
drawing lines on the plate.   
On the following day, 5 ml of agar solution containing ampicillin was added into 15 
ml tubes. With a tip, the colonies were picked by touching them carefully and placing 
the tip in the 5 ml agar solution. Around 10 colonies were picked in addition to a 
control tube that does not contain cells to confirm the absence of infection.  The tubes 
were then incubated overnight in a shaker set at 37°C.   
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7.2.3. Extraction and purification of plasmid DNA using Miniprep Kit  
 
After shaking the tubes overnight, they all appear to be full of cells except the control 
tube which should be clear. An aliquot of each clone should be frozen down by taking 
250 μl of warm glycerol into 1.5 ml Eppendorf tubes and adding 750 μl of culture 
medium for each tube and storing them at -80°C.    
The miniprep kit used for the extraction of plasmid DNA was the PureLink 
TM
 Quick 
Plasmid Miniprep (Invitrogen, UK). From the E-coli overnight culture, 2 ml were 
taken and put into a 2 ml Eppendorf tube and centrifuged at 13,000 rpm for 1 minute. 
After removing the supernatant medium, the pellet was resuspended in 250 μl 
Resuspension Buffer (R3) with RNase A, 250 μl of Lysis Buffer (L7) were added and 
the tubes were mixed gently by inverting the capped tubes 5 times. The tubes were 
then incubated for no more than 5 minutes at room temperature and 350 μl of 
Precipitation Buffer (N4) were added to the cells and the tubes mixed immediately by 
inverting the tubes until the solution is homogenous. The mixture was centrifuged at 
12,000 x g for 10 minutes at room temperature using a microcentrifuge to clarify the 
lysate from the lysis debris. The supernatant was loaded onto a Spin Column which 
was then placed into a 2 ml wash Tube and centrifuged at 12,000 x g for 1 minute. 
After discarding the flow-through, the column was put back into the Wash Tube and 
700 μl of Wash Buffer (W9) containing ethanol were added, the column was 
centrifuged at 12,000 x g for 1 minute. After discarding the flow-through, the column 
was placed back into the Wash Tube and centrifuged again at 12,000 x g for 1 minute 
to remove any residual Wash Buffer (W9). The Wash Tube was discarded with the  
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flow-through and the column placed in a clean 1.5 ml Recovery Tube. The next step 
consisted of adding 75 μl of preheated TE Buffer (TE) to the centre of the column 
which was left to incubate for 1 minute at room temperature.  Another centrifugation 
was carried out for 2 minutes at 12,000 x g and the purified plasmid DNA was 
retrieved in the Recovery Tube and can be stored at -20°C.  
 
7.2.4. EcoR1 restriction enzyme digestion of DNA plasmid 
 
In order to check the presence of the target gene (in this case IFNA1) into the DNA 
plasmid, 5 μl of the DNA solution was transferred in Eppendorf tubes with 1 μl of 
EcoR1 (Invitrogen, UK) enzyme, 2 μl of 10X buffer from EcoR1 kit and 12 μl of 
DEPC water. The tubes were then incubated at 37°C for 60 minutes. The products 
were run on a 1% agarose gel electrophoresis to confirm the EcoR1 treatment; control 
tubes have been prepared by adding 4 μl of uncut DNA plasmid with 4 μl of water 
and 2 μl of 6X loading buffer. For the digested samples, 5 μl of 6X loading buffer was 
added in each tube. All the samples were loaded on the gel by alternatively putting 
uncut and cut products. Visualisation of the gel using the alpha imager confirmed the 
presence the IFNA1 cDNA into the plasmid vector (Figure 7.1). Different clones were 
selected and sent for sequencing to a company called Cogenics which provides a full 
range of genomics services for both research and regulated projects (Essex, UK).  
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7.3. Results  
 
The digestion of the plasmid DNA with EcoR1 enzyme was verified by running cut 
and uncut DNA on a 1% agarose gel electrophoresis. Figure 7.2 shows the digestion 
of eight DNA plasmid products with the products of the digested DNA showing two  
bands where the bottom one corresponds to the IFNA1 cDNA with a size of 691bp 
and the upper band corresponds to the plasmid cDNA..  For sample number 2, the 
results of the digestion are negative which may be caused by the absence of cDNA.   
 
 
Figure 7.2: Agarose gel image of plasmid cDNA treated with ECOR1 enzyme. U 
(Uncut) and the control samples where no enzyme was added and C (Cut) are the 
cDNA samples digested with EcoR1 resulting on 2 bands: the upper one corresponds 
to plasmid cDNA and the bottom one to IFNA1 cDNA with a size of 691 bp.    
 
 
The results from the sequencing obtained after three weeks from Cogenics are 
summarised in Table 7.1. The different sequences have been analysed using Chromas 
software (version 2.33) available from the internet  
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(http://www.technelysium.com.au/chromas.html). After analysing the sequences using 
Chromas, they were compared to the cDNA sequence of the gene IFNA1. The 
percentage of similarity between the sequences and the IFNA1 gene are shown in the 
Table 7.1.  
 
 
 
Sample 
number 
Sample name Type 
Template 
/ Conc 
(ng/ l) 
Similarity 
(%) 
1 CPA86245_A12_T3P_L03.ab1 
Plasmid 
DNA  100 99 
2 CPA86245_B01_T3P_N03.ab1 
Plasmid 
DNA  100 99 
3 CPA86245_B02_T3P_P03.ab1 
Plasmid 
DNA  100 100 
4 CPA86245_B03_T3P_B05.ab1 
Plasmid 
DNA  100 99 
5 CPA86245_B04_T3P_D05.ab1 
Plasmid 
DNA  100 99 
6 CPA86245_C04_T7P_L07.ab1 
Plasmid 
DNA  100 99 
7 CPA86245_C05_T7P_N07.ab1 
Plasmid 
DNA  100 99 
8 CPA86245_C06_T7P_P07.ab1 
Plasmid 
DNA  100 99 
9 CPA86245_C07_T7P_B09.ab1 
Plasmid 
DNA  100 99 
10 CPA86245_C08_T7P_D09.ab1 
Plasmid 
DNA  100 99 
 
Table 7.1: Results from sequencing of the clones DNA obtained after transfecting 
IFNA1 cDNA into plasmid vector. The clone number 3 displays 100% similarity to 
IFNA1 gene which means that it has no mutations.  
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7.4. Discussion  
 
The cDNA sequence obtained from the clone number 3 displays 100% similarity with 
the full cDNA sequence of the interferon alpha 1 gene. In other words, no PCR errors 
have occurred in that clone which will then be transferred into mammalian cell 
expression vector (pcDNA3) and transfected in to the UACC-903 cell line as well as 
other melanoma cell lines in order to assess the suppression of tumourigenicity. 
HAPTER 6: REVISIONS OF CONCEPTUAL MODEL 
Chapter 8: Conclusions and Further Research   
       Page 159
   
 
 
 
 
 
 
CHAPTER 8 
 
CONCLUSIONS AND FURTHER RESEARCH 
CHAPTER 7: CONCLUSIONS AND FURTHER R 
8.1. General discussion and conclusion 
 
Cutaneous malignant melanoma is the most aggressive form of skin cancer and 
from a clinical perspective presents many challenges. Its incidence continues to 
increase in many countries and consequently this malignancy has attracted a lot of 
research interest as it became a significant health problem is several countries.   
The exact mechanisms by which melanoma occurs and develops remain unclear 
but it is well established that genetic as well as environmental factors such as UV 
exposure play a major role in the development of melanoma. Loss of 
heterozygosity deletions on different chromosomal regions such as 1p, 6q, 9p, 10q 
and 11q are observed during the development and progression of CMM, these 
cytogenetic regions are believed to contain critical tumour suppressor genes 
central to melanoma development. When TSG function is inactivated, the control 
of normal cell division may be lost contributing to the development of CMM. 
Genetic alteration of chromosome 9p appears to be a critical and frequent event in 
CMM development. Chromosomal aberrations such as LOH and homozygous 
 
8 
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deletion in various malignant cell lines including melanoma are regularly 
observed. Data suggest that critical loci which are distinct from the main TSG 
involved in melanoma CDKN2A, are believed to reside on the chromosomal 
region 9p21 adjacent to the INK4 locus (Parris et al., 1999; Pollock et al., 2001). 
Hence, the aim of this study as stated in chapter 1 was to identify novel tumour 
suppressor genes at chromosome 9p21 which may be important in CMM 
development 
The functional complementation technique of microcell mediated chromosome 
transfer technique was central to the research presented herein, and was used to 
construct cell hybrids by the transfer of a single chromosome 9 carrying a deletion 
at the INK4 locus (chromosome 9a) into the UACC-903 human malignant 
melanoma recipient cell line. In this way the effect of potential tumour suppressor 
loci on chromosome 9p21 could be examined independently of the presence of the 
CDKN2A gene P16. The constructed hybrids were afterwards analysed and tested 
for anchorage independent growth in a semi-solid medium as described in chapter 
4. Two types of hybrids were obtained: (a) segregant (tumourigenic) hybrids in 
which there was no suppression of anchorage independent growth in soft agar and 
which were classified as non suppressor hybrids and, (b) suppressor hybrids 
(suppression of tumourigenicity) that displayed no growth or a reduced capacity 
for anchorage independent growth in soft agar.  
To determine if differences in gene expression of loci located at chromosome 
9p21 were responsible for altered tumorigenicity in the segregant and suppressor 
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hybrid cell lines, gene expression analysis of 23 functional genes that are located 
in the chromosomal region 9p21 was conducted. Gene expression analysis of 
these gene in both suppressor and non suppressor hybrids as well as the UACC-
903 parental cell line and three other control cell lines, resulted in the 
identification of the two genes IFNE1 and IFNA1 as potential tumour suppressor 
genes. This is justified by the fact that these two genes exhibited expression in all 
the suppressor hybrids, whereas expression of these two genes was often absent in 
non suppressor hybrids, suggesting that the loss of these genes could be associated 
with a loss of tumour suppressor activity. Thus, chapter 6 presents an accurate 
approach to measure the levels of expression of IFNE1 and IFNA1 in the 
constructed hybrids. The findings derived from this approach suggest that the 
IFNE1 is not a candidate tumour suppressor gene because no significant 
difference was detected when the level of expression of this gene in suppressor 
and non suppressor hybrids was examined. The IFNE1 gene is a member of the 
type I interferon family and it is highly expressed in the brain but its biochemical 
and biological functions are poorly understood (Peng et al., 2007). In addition, the 
same authors reported that the anti-viral and anti-proliferative activities of the 
recombinant human IFNE1 gene were lower than other members of type I IFN 
such as IFNA2 (Peng et al., 2007). 
In the case of interferon alpha 1 gene, real-time PCR analysis revealed a 
difference in the level of expression of the IFNA1 gene between the suppressor 
and non suppressor hybrids. The levels of IFNA1 expression reflect the amount of 
cDNA of the gene in the suppressor versus non suppressor cell hybrids. 
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In Figure 6.12 it can be seen that the expression of IFNA1 in the suppressor 
hybrids is generally higher than the levels of expression in the non suppressor 
hybrids. Therefore, examination of the IFNA gene in this study provides evidence 
that it may be a potential tumour suppressor gene involved in the development of 
cutaneous malignant melanoma.  
Other studies have demonstrated that this gene is implicated in the induction of 
expression of p53 by boosting p53 responses to stress signals (Takaoka et al., 
2003). In addition, other studies confirmed that IFNA1 can directly inhibit the 
proliferation of tumour cells by down-regulating expression of oncogenes and 
inducing tumour suppressor genes such as p53, which can contribute to the 
antiproliferative activity of the IFN α cytokine (Ferrantini et al., 2007). 
 These observations lend weight to the findings presented in this study and 
confirm that IFNA1 may be a potential tumour suppressor gene itself or it has a 
critical role in the activation of other tumour suppressor genes implicated in the 
progression of cutaneous malignant melanoma.  
The type I interferon family are an important class of genes that encodes for 
cytokines which play a role in activation of the immune system, inhibition of viral 
replication and suppression of cell proliferation (Stark et al., 1998). These 
properties have given the type I IFN important roles in infections and cancer and a 
number of interferons are being used in therapies for many clinical conditions 
(Hardy et al., 2004). One of the applications of type I interferon for cancer 
therapy is for the treatment of melanoma. The interferon IFNα2b is an approved 
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therapy for melanoma, but has only shown to be clinically effective as adjuvant 
therapy of high risk melanoma cases (reviewed in Moschos and Kirkwood, 2007). 
Also, IFNα alone, even at high doses, does not cure all of the tested patients 
(Kirkwood et al., 1996). Currently, data from 12 randomized controlled trials 
using IFNα are available; they all failed to demonstrate a clear impact of IFNα 
therapy on overall survival in melanoma patients (Lens, 2006). These remarks 
suggest that this might depend on the genetic profile of individual patient‟s 
including the type of tumour and its stage and grade. However, the better 
understanding of the direct and the indirect anti-tumour roles of type I interferons 
in cancer in general and particularly melanoma, as well as the identification of all 
the mechanisms of type I interferons signalling and the mediation of immuno-
surveillance, will provide important information for the design of future 
treatments based on the use of interferons.  
 
8.2. Research limitations and future work  
 
As described and justified in the different chapters of the studies presented in this 
thesis, the collection and data interpretation used several cellular and molecular 
methodologies. The methods used have provided useful results where the 
application of the functional complementation technique of MMCT together with 
genes expression analysis has permitted the identification of a candidate TSG for 
CMM. But this research method has some limitations and as an example of these 
limitations, animal studies would have provided a more robust way to confirm the 
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type of the constructed hybrids as segregant or suppressor. In vivo tumourigenicity 
of the monochromsome hybrids consists in the inoculation of the suspended cells 
from various hybrids into nude mice followed by measurement of the tumours 
formed as described in Parris et al., 1999. However, this method was not used 
during this project because of the costs of animal studies as explained previously 
in chapter 3. Although anchorage independent assays using soft agar cloning is 
regarded as a reliable method for analysing tumourigenicity in a variety of tumour 
cell types (Shin et al., 1975).  
Moreover, it would have been interesting to examine the melanoma tumour cells 
for cytogenetic studies like FISH to retrieve the introduced chromosome 9 or its 
fragments and maybe carry out genotyping using microsatellite analysis to 
determine the deleted loci. Also, another possibility can be used to confirm the 
involvement of IFNA1 in the development of melanoma and which consists of the 
use of siRNA knock down against IFNA1 and its effects on tumourigenicity. If 
IFNA1 knock down results on increase proliferation and rapid tumour growth, it 
will confirm the tumour suppression properties of IFNA1 in CMM. Furthermore, 
testing IFNA1 protein using western blotting in cells taken at different stages of 
melanoma progression would provide an indication of changes of expression 
occurring in CMM. 
Initially, this study was carried out using only the highly tumourigenic malignant 
melanoma cell line UACC-903, which can be considered as a limitation. Further 
work to confirm the role of IFNA as a potential TSG for melanoma should 
involve the analysis of the expression of this gene in a number of tumorigenic 
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melanoma cell lines and melanoma tumour samples of different stage and grade. 
Additionally, it will be useful to construct hybrids using different recipient cell 
lines. In doing so, a range of hybrids will be available which will provide a larger 
opportunity to map and clone the candidate genes.  
Finally, to minimise the aforementioned limitations and in order to confirm the 
suppression effect of the IFNA1 gene in melanoma cell lines, the transfection of 
the cDNA of the IFNA1 gene into the UACC-903 and other melanoma cell lines 
is required and currently underway in our laboratory as explained in Chapter 7. 
This approach consists of a stable transfection. Melanoma cell lines stable 
transfected with the IFNA cDNA will be analysed for suppression of 
tumourigenicity using standard approaches described in this study.  
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